Document:

Exhibit 10.60

 

EXHIBIT 10.60

***Text Omitted and Filed Separately
Confidential Treatment
Requested
Under 17 C.F.R. §§ 200.80(b)(4)
and
240.24b-2(b)(1)

LICENSE AND DISTRIBUTION AGREEMENT

by and between

Immuno-Designed Molecules S.A.

and

Cambridge Laboratories Ltd.

 

			
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	2 / 36

TABLE OF CONTENTS

	 	 	 	 	 
	1 DEFINITIONS
	 	 	5	 
	2 APPOINTMENT
	 	 	8	 
	2.1 APPOINTMENT AND GRANT
	 	 	8	 
	2.2 SUB-DISTRIBUTION AND SUB-LICENSES
	 	 	8	 
	3 SCOPE OF APPOINTMENT
	 	 	8	 
	3.1 TERRITORY
	 	 	8	 
	3.2 COMPETITIVE PRODUCTS AND CLINICAL TRIALS
	 	 	9	 
	3.3 NEW INDICATIONS / ADDITIONAL TERRITORY
	 	 	10	 
	3.4 IMPROVEMENTS
	 	 	10	 
	3.4.1 Distributor’s Improvements
	 	 	10	 
	3.4.2 Development of Distributor’s Improvements
	 	 	11	 
	3.4.3 Supply of data by the Distributor
	 	 	11	 
	3.4.4 IDM Improvements
	 	 	11	 
	3.4.5 Rejection of IDM Improvements
	 	 	11	 
	4 UP-FRONT FEE / MILESTONES
	 	 	11	 
	4.1 UP-FRONT FEE
	 	 	11	 
	4.2 UP-FRONT FEE PARTIAL REIMBURSEMENT
	 	 	11	 
	4.3 REGISTRATION MILESTONE
	 	 	11	 
	4.4 NET SALES-RELATED PERFORMANCE ROYALTY
	 	 	12	 
	 
	 	 	 	 
	5 RELATIONSHIP BETWEEN THE PARTIES
	 	 	12	 
	5.1 INDEPENDENT CONTRACTORS
	 	 	12	 
	5.2 WHOLESALERS
	 	 	12	 
	5.3 IDM RESPONSIBILITIES AND OBLIGATIONS
	 	 	12	 
	6 REGULATORY
	 	 	12	 
	7 DISTIBUTOR’S DUTIES
	 	 	13	 
	7.1 GENERAL
	 	 	13	 
	7.2 PROMOTION, MARKETING AND SALES
	 	 	14	 
	7.3 COMMENCEMENT OF MARKETING
	 	 	15	 
	7.4 PROMOTIONAL MATERIALS
	 	 	15	 
	7.5 PROVISION OF Know-How
	 	 	16	 
	7.6 MINIMUM ANNUAL QUOTAS
	 	 	16	 
	 
	 	 	 	 
	8 IDM’S DUTIES
	 	 	16	 
	8.1 CONFORMITY OF PRODUCT
	 	 	16	 
	8.1.1 Compliance with Product Specifications
	 	 	16	 
	8.1.2 Claims of non-conformity
	 	 	16	 
	8.1.3 Non-conforming Product
	 	 	16	 
	8.1.4 Laboratory costs
	 	 	17	 
	8.1.5 Disclaimer
	 	 	17	 
	8.1.6 Warranty exclusions
	 	 	17	 
	8.1.7 Additional specifications
	 	 	17	 
	8.2 LICENSES TO PERFORM
	 	 	18	 
	8.3 MARKETING ASSISTANCE, PROVISION OF KNOW-HOW
	 	 	18	 
	 
	 	 	 	 
	9 COOPERATION BETWEEN PARTIES
	 	 	18	 
	9.1 MARKETING PLANNING
	 	 	18	 
	9.2 INTELLECTUAL PROPERTY RIGHTS
	 	 	18	 
	9.3 IDM’s PATENT OBLIGATIONS
	 	 	18	 
	9.4 IDM’S ORPHAN DRUG DESIGNATION OBLIGATIONS
	 	 	19	 
	10 FORECASTS AND ORDERS
	 	 	19	 
	10.1 FORECASTS
	 	 	19	 
	10.2 ORDERS
	 	 	20	 
	11 PRICE OF PRODUCT
	 	 	20	 
	11.1 CONDITION PRECEDENT
	 	 	20	 
	11.1.1 Public Price
	 	 	20	 
	11.1.2 No material adverse change
	 	 	20	 
	11.2 TRANSFER PRICE OF PRODUCT
	 	 	20	 
	11.3 ROYALTIES
	 	 	21	 
	11.4 ROYALTY PAYMENT AND RECONCILIATION
	 	 	21	 
	11.5 CURRENCY AND EXCHANGE RATES
	 	 	21	 

 

			
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	3 / 36

	 	 	 	 	 
	11.6 PRICE REVISION
	 	 	21	 
	11.6.1 Following Cost of Goods changes
	 	 	21	 
	11.6.2 Following commercial amendments
	 	 	21	 
	12 DELIVERY OF PRODUCT
	 	 	21	 
	13 RECORDS
	 	 	22	 
	13.1 RECORDS
	 	 	22	 
	13.2 LATE PAYMENTS
	 	 	22	 
	13.3 GUARANTEE
	 	 	22	 
	14 STORAGE — INVENTORY — RETURNS
	 	 	22	 
	14.1 STORAGE
	 	 	22	 
	14.2 RETURN OF PRODUCT
	 	 	22	 
	15 QUALITY
	 	 	22	 
	15.1 QUALITY CONTROL
	 	 	22	 
	15.2 SUSPENSION OF DISTRIBUTION
	 	 	23	 
	15.3 PRODUCT RECALL
	 	 	23	 
	16 TRADEMARKS
	 	 	23	 
	16.1 USE OF TRADEMARKS
	 	 	23	 
	16.2 PRODUCT MARK INFRINGEMENT
	 	 	24	 
	16.3 MAINTENANCE OF THE TRADEMARKS
	 	 	25	 
	16.4 INACTIVE OR ABANDONED TRADEMARKS
	 	 	25	 
	 
	 	 	 	 
	17 TERM AND TERMINATION OF THE AGREEMENT
	 	 	25	 
	17.1 TERM OF THE AGREEMENT
	 	 	25	 
	17.2 TERMINATION
	 	 	25	 
	17.3 CHANGE OF CONTROL / ASSIGNMENT
	 	 	26	 
	17.4 CONSEQUENCES OF TERMINATION
	 	 	26	 
	18 CONSEQUENTIAL LOSS — INSURANCE
	 	 	27	 
	18.1 CONSEQUENTIAL LOSS
	 	 	27	 
	18.2 INSURANCE
	 	 	27	 
	19 INDEMNIFICATION
	 	 	28	 
	19.1 INDEMNIFICATION BY THE DISTRIBUTOR
	 	 	28	 
	19.2 INDEMNIFICATION BY IDM
	 	 	28	 
	19.3 INDEMNITY PROCEDURE
	 	 	29	 
	19.4 DEFENCE OF CLAIM
	 	 	29	 
	20 ACTIONS OF COMPETITORS, LITIGATION
	 	 	29	 
	21 CONFIDENTIALITY
	 	 	29	 
	21.1 CONFIDENTIAL INFORMATION
	 	 	29	 
	21.2 PRIOR CONFIDENTIALITY AGREEMENT
	 	 	30	 
	22 GOVERNING LAW — DISPUTES
	 	 	30	 
	22.1 GOVERNING LAW
	 	 	30	 
	22.2 DISPUTES
	 	 	30	 
	22.2.1 Mediation
	 	 	30	 
	22.2.2 Arbitration
	 	 	30	 
	23 FORCE MAJEURE
	 	 	30	 
	24 REPRESENTATIONS AND WARRANTIES
	 	 	31	 
	24.1 REPRESENTATIONS AND WARRANTIES OF IDM
	 	 	31	 
	24.1.1 Organization and authority
	 	 	31	 
	24.1.2 No conflict
	 	 	31	 
	24.1.3 Ownership
	 	 	31	 
	24.1.4 Enforceability
	 	 	31	 
	24.1.5 Actions
	 	 	31	 
	24.1.6 No infringement
	 	 	31	 
	24.1.7 Warranty
	 	 	32	 
	24.2 REPRESENTATIONS AND WARRANTIES OF CL
	 	 	32	 
	24.2.1 Organization and authority
	 	 	32	 
	24.2.2 No conflict
	 	 	32	 
	25 MISCELLANEOUS
	 	 	32	 
	25.1 ENTIRE AGREEMENT
	 	 	32	 
	25.2 No WAIVER
	 	 	33	 
	25.3 PUBLIC ANNOUNCEMENTS
	 	 	33	 
	25.4 NOTICES
	 	 	33	 

 

			
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	4 / 36

	 	 	 	 	 
	25.5 SEVERABILITY
	 	 	34	 
	25.6 LANGUAGE
	 	 	34	 
	25.7 EXPENSES
	 	 	34	 
	26 SCHEDULES
	 	 	35	 
	26.1 SCHEDULE A
	 	 	35	 
	26.2 SCHEDULE B
	 	 	35	 
	26.3 SCHEDULE B-1
	 	 	35	 
	26.4 SCHEDULE C
	 	 	35	 
	26.5 SCHEDULE D
	 	 	35	 
	27 SCHEDULE E — PATENT LIST
	 	 	36	 

 

			
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	5 / 36

LICENSE AND DISTRIBUTION AGREEMENT

This License and Distribution Agreement (the “Agreement”) is made as of the Date of
Signature between:

IDM IMMUNO-DESIGNED MOLECULES S.A., a limited company organised and existing under the laws of
France, registered at Paris RCS under 382 632 263, whose office is at 172 rue de Charonne 75011
Paris FRANCE.

Hereinafter referred to as “IDM”

and

CAMBRIDGE LABORATORIES LTD. trading as CAMBRIDGE LABORATORIES IRELAND whose principal place of
business is Alexandra House, The Sweepstakes, Ballsbridge, Dublin 4, IRELAND.

Hereinafter referred to as “CL” or “Distributor”.

RECITALS

1. CL is engaged in the business of promoting, marketing, selling and distributing certain
pharmaceutical products.

2. IDM desires to appoint the Distributor as its exclusive distributor of the Product in the
Territory and the Distributor desires to accept such appointment subject to the terms of this
Agreement.

AGREED TERMS

1 DEFINITIONS

When used in this Agreement, including the Recitals and the Schedules (which are an integral part
of this Agreement) and unless otherwise expressly indicated, the following terms shall have the
following meanings:

Adverse Events means any undesirable event (from any source, including consumers or competitors)
including serious adverse events reported to the Distributor or of which the Distributor becomes
aware, and, in particular, those events relating to the Product in respect of which the Parties’
respective obligations are set out in Schedule B.

Affiliates means with respect to any Party, any person that directly, or indirectly through one or
more intermediaries, controls or is controlled by or is under common Control with such Party. The
term control, for the purpose of this definition, with respect to the relationship between or among
two persons, means the possession, directly or indirectly or as trustee or executor of the power to
direct or cause the direction of the affairs or management of a person, whether through ownership
of voting securities or executor, by contract or otherwise, including, without limitation, the
ownership, directly or indirectly, of securities having the power to elect a majority of the board
of directors or similar body governing the affairs of such person.

Agreement means this agreement between the Parties.

Authorities means the competent authorities in the Territory in charge of determining and/or
approving the marketing, the pricing and/or the reimbursement (as applicable) of pharmaceutical
products.

Business Year means a calendar year or, in the case of the first Business Year, the remainder of
the calendar year current at the Effective Date.

			
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	6 / 36

Change of Control has the meaning set forth in Article 17.3.

Combination Products means any biotechnological or pharmaceutical composition
incorporating the active ingredient of the Product together with one or more additional products,
therapeutic agents or prophylactic agents.

Competitive Products means any product that competes with the Product in the Indication, including
for the avoidance of doubt, any products developed or licensed by the Distributor.

Confidential Information means all IDM Know-How and all other technical, scientific, commercial and
other data and information supplied by either Party or its Affiliates to the other relating to the
Product or the businesses of the Parties.

Confidentiality Agreement means the agreement between the Parties dated April 8, 2004.

Date of Signature means the date of signature of the Agreement by the last Party to sign it.

Delivery means delivery of Product CPT (2000 ICC Incoterms), but for Article 12 (b).

Distributor Know-How means all Know-How acquired by the Distributor during the course of the
Agreement which is in the Distributor’s possession and which the Distributor is free to disclose to
IDM without accounting to third parties.

Distributor Marketing Plan means the plan of Schedule D. This plan shall be due by the Distributor
no later than three (3) months before the Effective Date. This plan shall contain a complete
strategic and tactical marketing and sales plan. Headline content of the plan is placed in Schedule
D.

Dossier means the collection of clinical, technical, pharmacological, medical, regulatory,
scientific and other data, permits and granted approvals in the possession of IDM as at the Date of
Signature which IDM will supply to the Distributor, in the form in which it exists at IDM, as soon
as practicable following the Date of Signature.

Effective Date means the date of the first Delivery of the quantity of the Product first ordered by
CL pursuant to Article 10, fully complying with the Product Specifications and certified ready for
release to the market after the grant by the pricing Authority in the Territory of the Public
Price.

EMEA means the European Medicines Evaluation Agency or any successor authority.

GMP means as relevant to the Products, the principles and guidelines of good manufacturing practice
as contained in a directive 2003/94/EC (medicinal products for human use), as such principles and
guidelines are interpreted and expanded in “The Rules Governing Medicinal Products in the European
Community, Volume IV. Good Manufacturing Practice for Medicinal Products”.

IDM Know How means the Dossier and all Know-How acquired by IDM during the course of the Agreement
which is in IDM’s possession and which IDM is free to disclose to the Distributor without
accounting to third parties.

IDM Site means any IDM manufacturing and/or storage site.

Improvements means any and all improvements, modifications and developments relating to the Product
including, but not limited to, those that will improve the Product’s quality, bioavailability, side
effect profile, solubility, efficacy or patient or medical professional acceptance and /or
compliance and shall include, but not be limited to, extensions of the label claims for the
Product, line extensions, new dosage forms of the Product, new delivery systems, development of an
isomer, polymorph, salt, ester, analogue or derivative of the Product or the active substance of
the Product or any metabolite and any Combination Product.

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	7/36

Indication means osteosarcoma

Initial Term means ten (10) years following the Effective Date of the Agreement or the date of the
last of the patents listed in the Schedule E related to the product and applicable in the Territory
to expire whichever is the longest.

Know-How means all technical, clinical, regulatory, medical and commercial data and other
information relating to the Product developed or acquired by either Party in the course of this
Agreement which is necessary or useful for the activities contemplated hereby. Know-How does not
include details on how to manufacture the Product.

Marketing Approval means the marketing authorisation granted by the Authorities such as, but not
limited to, EMEA.

Minimum Annual Quotas means the quantities of Product to be purchased by the Distributor during
each Business Year as agreed between the Parties and set forth in Schedule C, as amended from time
to time in writing.

Net Sales means, [...***...]

New Indication means any indication other than the Indication.

Parties means IDM and the Distributor and their respective successors in title.

Party means either IDM or the Distributor and their respective successors in title.

Patents means the patent application IDM intends to file in respect of the manufacturing process
for the Product and any other Product related claiming patents or applications for such existing
now or at any time during the term of this Agreement together with (a) all patents in the Territory
issuing from said applications; (b) any additions, divisions, continuations, continuations-in-part,
amendments, amalgamations, reissues, and re-examinations of such applications or patents in the
Territory; (c) any confirmation, importation and registration patents and patent applications in
the Territory in whatever legal form and by whatever legal title they are granted.

Product means a package comprising one (1) vial containing [...***...] MTP-PE ready to be
administered to patients in the Indication. The package delivered by IDM will be in its finished
form, ready for resale by the Distributor in the Territory as specifically described in Schedule A.

Product Marks means any trademark, service mark, trade name, domain name and logo used on or in
connection with the identification of the Products. IDM Marks means the IDM name and logo or any
other corporate related names or logos controlled by IDM or its Affiliates at the Effective Date or
at any time during the term of this Agreement and which are used in connection with the services to
be performed under this Agreement or otherwise in connection with this Agreement. For the purposes
hereof, the term control shall mean the possession of the ability to grant the right, to license or
sublicense, without violating the terms of any agreement or other arrangement with any third party

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested

under 17 C.F.R. §§ 200.80(b)(4) and

240.24b-2(b)(1)

 

 

			
	May 10, 2005
	 	8/36

existing at the time of the grant of right, license or sublicense.

Product Specifications are set forth in Schedule A. Schedule A shall be those set forth in the
Marketing Approval and may be amended and supplemented from time to time in writing following the
prior approval of the Authorities. Schedule A also contains a description of the current packaging
of the Product, however, each time the packaging of the Product is modified in accordance with the
procedures set forth in Schedule B-1 and following prior approval of the Authorities, Schedule A
shall be deemed to have been modified accordingly.

Public Price means the price, approved by the Authorities, to be paid by a patient (or his or her
insurers) or a payer for the Product in the Territory or, if less, the maximum level of
reimbursement in respect of the Product approved by the Authorities.

Regulatory Approval(s) means any permissions other than the Marketing Approval to be obtained from
the Authorities which are necessary for the importation, promotion, marketing, use, sale and
distribution of the Product in the Territory, including the definition of the Public Price of the
Product and reimbursement conditions as well as the obtaining of such Public Price and any
variation of any such permission.

Standard Operating Procedures are described in Schedule B. The Standard Operating Procedures may
be amended and supplemented by IDM from time to time upon not less than forty five (45) days’
prior notice to the Distributor, provided that such modifications are reasonable and that IDM
shall consult with the Distributor prior to such modification to ensure that it does not violate
applicable laws and regulations relating to the delivery, storage and transport of pharmaceutical
products.

Territory means United Kingdom and Republic of Ireland.

Trademarks means the IDM Marks and the Product Marks.

Transfer Price shall have the meaning set forth in Article 11.2.

2 APPOINTMENT

2.1 APPOINTMENT AND GRANT

Subject to the terms and conditions set forth herein IDM hereby:

	(a)	 	appoints the Distributor from the Date of Signature as its exclusive distributor to promote,
market, sell, distribute and subject to Articles 3.2 and 3.4, develop the Product in the
Territory for the Indication and the Distributor hereby accepts such an appointment; and
	 
	(b)	 	grants to the Distributor (i) a non-transferable save as provided in Article 17.3, exclusive
license to use the Patents, Product Marks, the IDM Know How and the Know-How in the Territory
and (H) a non-transferable, non-exclusive, non assignable, save as Article 17.3, license to
use the IDM Marks, in connection with the Distributor’s promotion, marketing, sale and
distribution of the Product for the Indication in the Territory.

2.2 SUB-DISTRIBUTION AND SUB-LICENSES

Nothing in this Agreement shall entitle the Distributor to grant sub-distribution rights or
sub-licenses in relation to the Product, the Patent, the IDM Know-How or the Trademarks to any
third party that is not an affiliate, without the prior written consent of IDM which shall not be
unreasonably withheld or delayed.

3 SCOPE OF APPOINTMENT

3.1 TERRITORY

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	9 / 36

	(a)	 	The rights granted to the Distributor are limited to the promotion, marketing, sale,
distribution and subject to Articles 3.2 and 3.4, development of the Product within the
Territory. Throughout the term of the Agreement, the Distributor and/or, where applicable, its
Affiliates shall not, directly or indirectly, pursue an active sales policy (i.e. promote,
market and sale the Product) outside the Territory. The Distributor and/or, where applicable,
its Affiliates shall not, in particular, actively approach customers outside the Territory by
direct mail, visits, advertisements or other promotions unless Distributor wishes to utilise
the expertise of such a customer in order to further its marketing effort within the
Territory. The Distributor and/or, where applicable, its Affiliates shall not otherwise seek
orders for Product from customers outside the Territory. It is acknowledged that having
details of the Product on its web site shall not constitute actively promoting or marketing
the Product outside the Territory by the Distributor.
	 
	(b)	 	If the Distributor has been granted the rights set forth in paragraph (a) above for (i) a
State of the European Union (EU) or the European Economic Area (EEA), (ii) a State having
entered into a Europe agreement with the EU or (iii) a State from which re-imports towards the
EU or the EEA are reasonably foreseeable, the Distributor may respond to unsolicited requests
from customers located in the EU, the EEA or a State having entered into a Europe agreement
with the EU, it being agreed that:

	 	(i)	 	The Distributor and/or, where applicable, its Affiliates may only respond to
demands from these customers for as long as they dispose of sufficient stocks to meet
orders from customers inside the Territory;
	 
	 	(ii)	 	No modification of the substantial qualities of the Product may be made at any time.

	(c)	 	In the event that the Distributor has been granted the rights set forth in paragraph (a)
above for a territory other than those defined in paragraph (b) above, the Distributors may
respond to unsolicited requests from customers outside of the Territory only if such customers
are located in the EU, the EEA or in a State having entered into a Europe agreement with the
EU.
	 
	(d)	 	This commitment shall survive after expiration or termination of the Agreement for as long as
the Distributor may, in accordance with the terms and conditions set forth in Article 17.4,
continue to sell the Product remaining in its stocks.
	 
	(e)	 	IDM retains rights for use of the Product outside of the Territory.

3.2 COMPETITIVE PRODUCTS AND CLINICAL TRIALS

Save as set forth below and in Articles 3.4.1 and 3.4.2, IDM will be responsible for all
development work including but not limited to future eventual clinical trials on the Product in the
Indication, any other indications and Improvements and all related expenses. In such circumstances,
IDM will share with and make available to CL all clinical and safety data, regulatory materials and
information related to the Product and the Indication that CL might need.

The Distributor shall be entitled to conduct or finance via third parties, its own additional
clinical trials for both marketing and development purposes. If Distributor wishes to undertake
such additional clinical trials Distributor must seek prior written consent and approval from IDM
which shall not be unreasonably withheld or delayed.

As a condition to consenting to the use of the Products in a clinical trial, IDM shall have
[...***...] right to use for any and all purposes outside the Territory, all information relating
to the Products resulting from such a clinical trial. To the extent IDM has approved the use of the
Products by the Distributor in a clinical trial, IDM shall provide reasonable quantities of the
Products to the Distributor solely for such use at Distributor’s cost.

			
	 	 	 
	IDM Initial
	 	CL Initial

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested

under 17 C.F.R. §§ 200.80(b)(4) and

240.24b-2(b)(1)

 

 

			
	May 10, 2005
	 	10 / 36

The Distributor, for itself and/or, where applicable, its Affiliates, undertakes not to, directly
or indirectly, promote, market, sell, manufacture, import or distribute any Competitive Products in
the Territory for a period of five (5) years from the Effective Date. Furthermore, the Distributor
represents and warrants that, as of the Date of Signature, neither the Distributor nor, where
applicable, its Affiliates, directly or indirectly promote, market, sell, manufacture, import, or
distribute or use in clinical trials, any Competitive Products in the Territory.

The Distributor recognizes that the obligation contained in this Article 3.2 is indispensable to
protect the IDM Know-How disclosed to the Distributor and that this obligation shall therefore
survive, for a period of one (1) year after the termination of this Agreement.

3.3 NEW INDICATIONS / ADDITIONAL TERRITORY

	(a)	 	IDM grants to Distributor a first option to be appointed as its distributor of the Product
for a New Indication in the Territory on conceptually similar terms to those set forth herein,
and if the Distributor accepts such appointment, the Distributor shall communicate its
acceptance in writing to IDM within thirty (30) days of receipt of IDM’s offer. In such case,
the Distributor’s distribution of the product in the New Indication shall be governed by this
Agreement, to the extent not modified by the aforementioned conceptually similar terms as
agreed between the Parties. Should the Parties fail to agree on such conceptually similar
terms within thirty (30) days of receipt of IDM’s offer, then the Chief Executive Officers
shall attempt for a period not more than thirty (30) days to reach an agreement. If the CEOs
can not reach an agreement in the said thirty (30) days, the outcome shall finally be settled
by an independent analysis from a mutually agreed independent third party whose decision shall
be binding upon the Parties and cost of such independent analysis shall be paid entirely by
the Party that the independent third party rules against.
	 
	(b)	 	Failure by the Distributor to give notice of acceptance or rejection of IDM’s offer within
the thirty (30) day period set out in Article 3.3 (a) shall constitute a rejection of the
offer by the Distributor.
	 
	(c)	 	Although IDM may offer third parties the opportunity to license the Product in other
countries than the Territory, or otherwise seek to develop relationships with third parties
related to the Product in countries other than the Territory, IDM will inform CL of its
decision to license the Product in other countries which do not belong to the Territory.
Should such other countries interest CL that the Parties will negotiate with respect to the
exclusive distribution of the Product outside of the Territory where CL might promote, market,
sell and distribute the Product. For sake of clarity, until an amendment to the Licence
Agreement granting Additional Territory is not executed by the Parties, IDM shall be free to
discuss and negotiate with any third parties.
	 
	(d)	 	As of today, in the Territory. IDM owns exclusive rights concerning the use of the Product as
an agent to be used in the Indication. In the Indication, the Product has been granted an
Orphan Drug Status in both the US and European Union. IDM will be responsible for its own
research and development activities on the Product and will assume all related expenses.

3.4 IMPROVEMENTS

3.4.1 Distributor’s Improvements

Distributor shall promptly submit to IDM written information about any Improvements it may wish
to develop or acquire during the term of this Agreement. The Distributor may develop or acquire
such Improvements only after the prior written approval of IDM. The Distributor shall grant to IDM
a royalty-bearing exclusive license on Improvements to develop, register, manufacture, market, use,
distribute and sell, directly or indirectly, such Improvements in all countries of the world
outside the Territory. IDM may sub-license such Improvements to its non-Affiliated distributors and
licensees of the Product. Any Improvement developed by Distributor shall become a Product and be
governed by this agreement save that the royalty rate payable to IDM on Net Sales in the Territory
shall be reduced by the royalty rate agreed outside the Territory.

			
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	11 / 36

3.4.2 Development of Distributor’s Improvements

Subject to Articles 3.2 and 3.4.1, the Distributor shall conduct all development studies and
any clinical studies at its own expense and shall comply with all applicable regulatory and medical
requirements in the Territory.

3.4.3 Supply of data by the Distributor

All information relating to any Distributor Improvements shall be submitted by the Distributor
to IDM in the English language.

3.4.4 IDM Improvements

If IDM develops or acquires any Improvement, IDM shall offer to Distributor the possibility to
market, use, sell and distribute such Improvement in the Territory and any agreed additional
territory. If the Distributor wishes to accept such offer, Distributor shall communicate its
acceptance in writing to IDM within thirty (30) days of receipt of IDM’s offer. Any Improvement
offered by IDM to Distributor shall, if accepted by Distributor, become a Product and be governed
by this Agreement save for reasonable and justifiable commercial terms which will reflect the size
of the market for the Improvement in the Territory and any agreed additional territory. IDM shall
provide to Distributor quarterly written reports relating to any development of any Improvements it
is undertaking.

3.4.5 Rejection of IDM Improvements

Failure by Distributor to give notice of acceptance or rejection of any Improvement offered by
IDM within the thirty (30) day period set out in Article 3.4.4 shall constitute rejection of the
Improvement by Distributor. IDM shall be free to offer such rejected Improvement to one or more
third parties in the Territory and outside the Territory.

4 UP-FRONT FEE / MILESTONES

4.1
UP-FRONT FEE

In consideration of the appointment and the grant of rights set out in Article 2, the
Distributor shall pay to IDM an up-front fee amounting to [...***...] within sixty (60) days of the
Date of Signature. That sum shall be apportioned as follows [...***...] for the grant of rights
under the Trademarks, [...***...] for the grant of rights under the IDM Know How, [...***...] for
the grant of rights under the Patents. Payment shall be made by wire transfer to IDM’s nominated
bank account. Interest on late payments shall accrue at twelve (12) month EURIBOR plus three (3)
percent from the date payment becomes due until receipt of payment in full by IDM, or, if lower, at
the highest rate permitted by mandatory provisions of local law in the Territory. But for Article
4.2 and Article 24.1, the up-front fee shall not be subject to reimbursement whatever happens to
the Trademarks, IDM Know-How and Patents.

4.2 UP-FRONT FEE PARTIAL REIMBURSEMENT

CL has the right to terminate the Agreement, with a refund of [...***...] of the initial
[...***...] should IDM not be able to manufacture the Product according to the new process or is
unable to demonstrate its comparability to the Product from the original process to the
satisfaction of the regulatory Authorities in the Territory within thirty (30) months of the Date
of Signature. The remaining [...***...] of the initial [...***...] shall not be subject to
reimbursement by IDM save for a breach of the warranties set forth in Article 24.1.

4.3 REGISTRATION MILESTONE

In consideration of the grant of the Marketing Approval of the Product in the Territory, the
Distributor shall pay to IDM a milestone amounting to [...***...]

			
	 	 	 
	IDM Initial
	 	CL Initial

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested

under 17 C.F.R. §§ 200.80(b)(4) and

240.24b-2(b)(1)

 

 

			
	May 10, 2005
	 	12 / 36

[...***...] within sixty (60) days of the date of receipt of the IDM invoice. That sum shall be
apportioned as follows [...***...] for the grant of rights under the Trademarks, [...***...] for
the grant of rights under the IDM Know How, [...***...] for the grant of rights under the Patents.
Payment shall be made by wire transfer to IDM’s nominated bank account. Interest on late payments
shall accrue at twelve (12) month EURIBOR plus three (3) percent from the date payment becomes due
until receipt of payment in full by IDM, or, if lower, at the highest rate permitted by mandatory
provisions of local law in the Territory. This registration milestone shall not be subject to
reimbursement by IDM save for a breach of the warranties set forth in Article 24.1.

4.4 NET SALES-RELATED PERFORMANCE ROYALTY

Upon achievement of [...***...] of cumulative Net Sales in the Territory, the Distributor shall
pay to IDM a one off sales performance royalty amounting to [...***...] within sixty (60) days of
the date of receipt of invoice. Payment shall be made by wire transfer to IDM’s nominated bank
account. Interest on late payments shall accrue at twelve (12)-month EURIBOR plus three (3) percent
from the date payment becomes due until receipt of payment in full by IDM, or, if lower, at the
highest rate permitted by mandatory provisions of local law in the Territory.

5 RELATIONSHIP BETWEEN THE PARTIES

5.1
INDEPENDENT CONTRACTORS

The Distributor shall act as an independent contractor who purchases the Product and resells it
in its name and for its own account. Nothing in this Agreement shall constitute or be deemed to
constitute either Party as the legal representative or agent of the other, nor shall either Party
have the right or authority to assume, create, or incur any liability or any obligation of any
kind, expressed or implied, in the name or on behalf of the other Party.

5.2 WHOLESALERS

The Distributor shall be entitled to enter into such agreements with wholesalers as it deems
necessary in order to promote the sale of the Product in the Territory. The designation of such
wholesalers shall be the sole responsibility of the Distributor and IDM shall not have any
obligations towards these and/or other wholesalers either during the term of this Agreement or
after its termination. The Distributor shall indemnify and hold harmless IDM and/or, where
applicable, its Affiliates in respect of the acts and omissions of its wholesalers.

5.3 IDM RESPONSIBILITIES AND OBLIGATIONS

	(a)	 	IDM will be responsible for GMP compliant manufacture of the Product, confirmed by a
Certificate of Conformance
	 
	(b)	 	In respect of the terms of the agreement signed between Ciba-Geigy and TherAtid, Inc.
(TherAtid, Inc merged with Jenner Technologies Corporation in 1996, which became Jenner
Biotherapies Inc., holder of the Product rights. Those rights were acquired by IDM in 2003)
and effective since April 4, 1996, IDM will be responsible for all payments due to Ciba-Geigy
(now Novartis).
	 
	(c)	 	IDM will be responsible for pharmaco-vigilance and drug safety monitoring and shall comply at
all times with Volume 9 of the “The Rules Governing Medicinal Products in the European
Community’. Without limiting the generality of the foregoing, IDM shall provide to Distributor
all information necessary to enable Distributor to fulfil its obligations as national
representative in the Territory.

6 REGULATORY

IDM is responsible for all regulatory activities when they are related to obtaining any
Marketing Approval or post-authorization variation applications for the Product. IDM will use its
commercially reasonable endeavours to obtain the Marketing Approval of the Product and the approval
of post-authorisation variation applications through the centralised procedure of the EMEA in the
Indication

			
	 	 	 
	IDM Initial
	 	CL Initial

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested

under 17 C.F.R. §§ 200.80(b)(4) and

240.24b-2(b)(1)

 

 

			
	May 10, 2005
	 	13 / 36

and any further indication. IDM shall be free to interact directly with EMEA regarding the
Marketing Approval and require any European national Authorities to be its rapporteur and
co-rapporteur. IDM shall keep Distributor duly informed of progress with the application for the
Marketing Approval including, but not limited to, progress with the manufacturing comparability
study. Without limiting the generality of the foregoing, IDM shall provide updates by
teleconference and minutes of the teleconference at least every two (2) months, or more frequently
as necessary, setting forth all relevant information regarding progress with the application for
the Marketing Approval and any problems encountered.

If Marketing Approval is not obtained within thirty (30) months from the Date of Signature, CL
shall have the right to terminate the Agreement according to Article 17.2.

The Distributor shall:

	(a)	 	employ its reasonable efforts and do everything as is reasonably necessary, to help IDM to
obtain the Marketing Approval in accordance with the timelines agreed upon by the Parties;
	 
	(b)	 	inform IDM, in a timely manner, before exchanging any information material with an Authority
and provide IDM with a copy, via fax, followed by a copy by mail, of any information provided
to the Authority or where information was given orally, with a written summary of such
information as well as with a copy of any and all correspondence received from any Authority
in relation to any Regulatory Approval, immediately upon receipt;
	 
	(c)	 	obtain and maintain any necessary Regulatory Approval and pay all necessary fees related to
such Regulatory Approval to the Authorities promptly when due;
	 
	(d)	 	act as national representative for IDM in the Territory with regard to Product-related
regulatory affairs in the Territory;
	 
	(e)	 	promptly advise IDM in writing of all applicable laws, rules and regulations of the Territory
relating to the Marketing Approval, distribution, advertising, promotion and sale of the
Product in the Territory, as well as of all governmental initiatives and proposals which could
affect such laws, rules or regulations;
	 
	(f)	 	provide regular written timetables (at least every three (3) months) to IDM for the ongoing
regulatory and pricing activities (expected date of submission, expected date of approval,
grant of Public Price and grant of reimbursement) and justification for any change to such
timetables.

7 DISTRIBUTOR’S DUTIES

7.1 GENERAL

The Distributor shall:

	(a)	 	use its commercially reasonable efforts to promote, market, sell and distribute the Product
in the Territory;
	 
	(b)	 	maintain a prompt delivery service compatible with the current Good Distribution Practices,
good business practices, the nature of the Product and the requirements of its customers, in
line with the Standard Operating Procedures and any other guidelines given by IDM from time to
time in writing;
	 
	(c)	 	ensure that the transportation and storage of the Product are in line with the Standard
Operating Procedures and shall at all times preserve the quality of the Product;

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	14 / 36

	(d)	 	make no safety or performance claim in respect of the Products which has not been previously
approved by IDM;
	 
	 	 	conduct its business in a responsible and ethical manner and comply, with the information
and reasonable recommendations communicated in writing to it by IDM and with all applicable
laws, rules and regulations concerning the labelling, packaging, warehousing and
distribution of the Products;
	 
	(f)	 	maintain, for the longer of either two (2) years after the termination of the Agreement or
such other period as it is required under applicable rules and regulations, all
pharmaco-vigilance data and recall systems and records, as well as such other information as
shall reasonably be required to effect a recall of the Product;
	 
	(g)	 	notify IDM within five (5) business days upon it’s becoming aware of any occurrence of
disparagement of the Product or infringement of any rights relating to the Product in the
Territory;
	 
	(h)	 	comply with all laws and regulations in the Territory and in any agreed additional territory
in relation to the use of Internet for the promotion, advertising and provision of information
in relation to pharmaceutical products to both private and professional users; in particular,
the Distributor shall ensure that any proposed reference to the Product on a website owned,
managed or sponsored by the Distributor shall adhere to all reasonable instructions of IDM
regarding the content and construction of any such website save that IDM acknowledges that its
wishes will be subordinate to the rule set forth by any authorities in the Territory and in
any agreed territory. In no event shall the Distributor provide any hypertext or other link to
an IDM website or register a domain name incorporating a Trademark without the express written
approval of IDM;
	 
	(i)	 	agree to share and make available to IDM all information related to pricing, regulatory
affairs, drug safety and marketing strategy.

7.2 PROMOTION, MARKETING AND SALES

The Distributor shall:

	(a)	 	Promote, market, sell and distribute the Product in accordance with the Distributor Marketing
Plan as agreed between the Parties and utilise an appropriate number of suitably qualified and
experienced sales and marketing people to fulfil its obligations under this article and
Article 7.1 (a);
	 
	(b)	 	promote the Product in first detail position with the relevant sales team to paediatric
oncologists for a period of at least the first two (2) years from the Effective Date;
	 
	(c)	 	establish and maintain strong links with leading teaching hospitals, academic institutions
and key opinion leaders in the Territory in order to enhance the visibility of the Product;
	 
	(d)	 	maintain a permanent stock of the Product equal to at least one (1) month’s sales based on
the average monthly forecasted sales from Distributor to customers of the following four (4)
months;
	 
	(e)	 	sell Product in the same containers, with the same labels and packaging as received;
	 
	(f)	 	provide to IDM the following written reports:

	 	(i)	 	on a quarterly basis during the first twelve (12) months following the
Marketing Approval: estimated number of patients, names of customers or wholesalers and
quantities of volumes shipped to customers or wholesalers (including sales, free or
discounted samples if applicable), inventory (including lot numbers), revenues, rolling
twelve (12) month demand and sales forecasts for sales, free or discounted samples, if
applicable. After the first twelve

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	15 / 36

	 	 	 	(12) months the frequency and content of this report shall be discussed between the
Parties and modified as agreed;
	 
	 	(ii)	 	on a semi-annual basis: business progress, marketing strategy and tactics,
sales planning;
	 
	 	(iii)	 	on an annual basis: annual business review; future year’s annual business
plan, including the year’s annual sales, the pricing and patient and unit volume
targets;

	(g)	 	comply with the Standard Operating Procedures;
	 
	(h)	 	promptly report to IDM within forty eight (48) hours from having knowledge of it all Serious
Adverse Events and within a reasonable delay all Adverse Events reasonably likely to be
associated with the use of the Product and all complaints relating to material defects of the
Product. The Parties’ respective pharmaco-vigilance obligations are set out in Schedule B;
	 
	(i)	 	establish and maintain systems and records to enable IDM to recall and recover the Product in
a timely, efficient and accurate manner and also in accordance with applicable laws and
regulations and permit IDM to periodically check that such records are being maintained
properly.

7.3 COMMENCEMENT OF MARKETING

	(a)	 	The Distributor shall commence to promote, market, distribute and sell the Product in the
Territory within three (3) months of the Effective Date.
	 
	(b)	 	The Distributor shall be deemed to have commenced to market the Product commercially in the
Territory only when it shall have commenced to promote the sale of the Product in the
Territory in accordance with the Distributor Marketing Plan and offered it for sale in the
Territory. All costs and expenses of promoting, marketing, distributing and selling the
Products shall be borne by the Distributor.

7.4 PROMOTIONAL MATERIALS

	(a)	 	IDM shall provide to Distributor examples of all promotional materials used in relation to
the Product in other countries in the EU, if any, along with clear written guidelines on the
overall international communication strategy developed by IDM in relation to the Product, if
any, which Distributor shall use as the basis of its communication strategy in the Territory.
	 
	(b)	 	The Distributor shall send to IDM one (1) copy of each of the promotional and sales materials
proposed to be used by the Distributor, including relevant Distributor web site pages, and
ensure that IDM is consulted during the development of all those materials. IDM will be
integrated into Distributors formal sign off procedure for all such materials providing its
comments within five (5) business days after receipt. The Distributor shall comply with all
reasonable comments made by IDM. If no comments are received within the said five (5) business
days it will be assumed that IDM has no comments on the materials.
	 
	(c)	 	Once promotional materials have completed the formal sign off procedure, the Distributor
shall promptly supply to IDM samples (with an English translation) of advertisements,
promotional literature, sales aids, training material for salesmen and other materials,
including relevant Distributor web site pages, used by the Distributor in connection with the
promotion, marketing, distribution and sale of the Product.
	 
	(d)	 	All technical and scientific information and therapeutic claims used or referred to by the
Distributor in advertisements, promotional literature, sales aids and training aids with
respect

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	16 / 36

	 	 	to the Product shall be consistent with local legal requirements in the Territory and any
Marketing and Regulatory Approval.

7.5 PROVISION OF KNOW-HOW

The Distributor shall supply IDM with Distributor Know-How as it becomes available.

7.6 MINIMUM ANNUAL QUOTAS

The Distributor undertakes to achieve the Minimum Annual Quotas in each Business Year. IDM
acknowledges that this obligation is dependent on IDM supplying to Distributor the quantities of
the Product ordered by Distributor in the times set forth in the orders such Product to be fully
compliant with the Product Specifications and GMP and to have been certified by IDM’s Qualified
Person to be suitable for release to the market. Furthermore the Minimum Annual Quotas are based on
the assumption that the Product will be able to be sold reimbursable and if that transpires not to
be the case the Minimum Annual Quotas will not apply. The Minimum Annual Quotas are set forth in
Schedule C. In the event that Distributor fails in two (2) consecutive Business Years to achieve
the cumulative Minimum Annual Quotas for the Business Years Distributor shall have the right to pay
to IDM a sum equal to the then applicable royalty rate multiplied by the cumulative Minimum Annual
Quotas for those two (2) Business Years less the royalties actually paid to IDM for those two (2)
Business Years. If Distributor does not elect to make such a payment IDM shall have the right to
terminate this Agreement based on Article 17.2 (c) (ii). For the sake of clarity termination shall
be the sole remedy available to IDM in such circumstances.

8 IDM’S DUTIES

8.1 CONFORMITY OF PRODUCT

8.1.1 Compliance with Product Specifications

The Product sold to the Distributor shall have been manufactured in accordance with GMP and
shall comply with the Product Specifications for the shelf life of the Product. IDM shall, prior to
delivery of any order of Product, send to Distributor a Certificate of Analysis and a Certificate
of Conformance signed by IDM’s Qualified Person confirming the Product is suitable for release to
the market. At Distributor’s request IDM shall provide a copy of the batch manufacturing records to
Distributor. IDM acknowledges that Distributor will not be performing any further testing and will
rely on the certifications by IDM and its Qualified Person. Distributor shall notify IDM when it is
prepared to accept delivery of an order of the Product. Distributor shall notify IDM as soon as
possible after becoming aware that the Product fails to meet the Product Specifications. If the
Product fails to meet the Product Specifications, all batches of the non-conforming Product shall
be replaced by IDM at IDM’s expense, unless the non-conformity was caused by the negligence of the
Distributor or any other party than IDM after Delivery.

8.1.2 Claims of non-conformity

If IDM does not accept the Distributor’s claim of non-conformity after re-analysis, the Parties
shall nominate an independent, reputable laboratory, acceptable to both Parties (or, failing
agreement, nominated by the Chairman of the International Association for Pharmaceutical Technology
- APV), that shall repeat the methods of analysis set out in the Standard Operating Procedures on
representative samples from the same batch provided by both the Distributor and IDM. The resulting
determinations shall be binding on the Parties.

8.1.3 Non-conforming Product

Any quantity of the Product finally determined to be not in conformity with the Product
Specifications shall, at the option of IDM and at IDM’s expense (except where the non-conformity is
due to the negligence of the Distributor or any party other than IDM after Delivery), either be
returned to IDM or destroyed in accordance with instructions to be provided by IDM and replaced.
Pending final

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	17 / 36

determination, and if so requested by the Distributor in writing, IDM shall endeavour promptly to
send a new batch of the Product (of similar quantity as to the amount of the Product being analysed
pursuant to Article 8.1.2) to the Distributor. If, as the result of a batch not conforming to
specification according to Articles 8.1.1 or 8.1.2, the Distributor does not meet its Minimum
Annual Quota for that Business Year such Business Year shall not be taken into account as one of
the two (2) Business Years referred to in Article 7.6.

8.1.4 Laboratory costs

The costs of the independent laboratory referred to in Article 8.1.2 shall be borne by (i) the
Distributor if the Product is determined to conform to the Product Specifications or not conform to
such specifications due to the negligence of the Distributor or any party other than IDM after
Delivery; or (ii) IDM if the Product is determined not to conform to the Product Specifications.

8.1.5 Disclaimer

Except as set forth in Article 8.1.1, 5.3 (a) and 24 and to the extent permitted by applicable
law, IDM disclaims any warranties or representations, express or implied, with regard to the
Product including, without limitation, any warranties that the Product is suitable for a particular
use or purpose.

8.1.6 Warranty exclusions

The warranty provided in Article 8.1.1 shall not apply to any non-conformity of the Product
resulting from alteration, misuse, negligence, mishandling or storage in an improper environment by
the Distributor or any party other than IDM after Delivery by IDM.

8.1.7 Additional specifications

In the event that the Authorities require additional specifications for the Product and IDM
considers that those additional specifications concerning the Product would require IDM or its
Affiliates to make investments or modifications in the manufacturing of the Product which would in
IDM’s reasonable view, make the continued manufacture and supply of the Product no longer
commercially viable it shall notify Distributor of such and provide Distributor with all relevant
information about the additional specifications required and the investment entailed. The Parties
shall, as soon as practical thereafter but in any event no later than twenty (21) days from the
date of notification by IDM, meet to discuss potential solutions. Should IDM, following that
meeting, still hold the reasonable view that the continued manufacture and supply of the Product is
no longer commercially viable IDM shall give Distributor the option of:

Option 1 — sharing the costs of meeting the additional specifications with IDM and agreeing
appropriate amendments to the commercial terms of this Agreement with respect to, inter alia, the
royalty rate payable by Distributor to reflect the change in manufacturing circumstances and the
investment made by Distributor in meeting the additional specifications for the Product. If the
Parties can not agree appropriate commercial amendments the Chief Executive Officers of each Party
shall attempt for a period of not more than sixty (60) days to reach an agreement. If the Chief
Executive Officers can not reach an agreement in the said sixty (60) days, the outcome shall
finally be settled by an independent analysis from a mutually agreed independent third party whose
decision shall be binding upon the Parties and the cost of such independent analysis shall be paid
entirely by the Party that the independent third party rules against.

Option 2 — bearing entirely the cost of meeting the additional specifications and agreeing
appropriate amendments to the commercial terms of this Agreement with respect to, inter alia, the
royalty rate payable by Distributor to reflect the change in manufacturing circumstances and the
investment made by Distributor in meeting the additional specifications for the Product. If the
Parties can not agree appropriate commercial amendments the Chief Executive Officers of each Party
shall attempt for a period of not more than sixty (60) days to reach an agreement. If the Chief
Executive Officers can not reach an agreement in the said sixty (60) days, the outcome shall
finally be settled by an independent analysis from a mutually agreed independent third party whose
decision shall be binding upon the Parties and the cost of such independent analysis shall be paid
entirely by the Party that the

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	18 / 36

independent third party rules against.

Should both IDM and CL agree that meeting the additional specifications is not commercially viable
then the Agreement shall be terminated by mutual consent.

8.2 LICENSES TO PERFORM

IDM shall obtain and maintain in its name or in the name of its Affiliates all licenses,
approvals and permits (other than the Regulatory Approvals which must be obtained by the
Distributor) necessary for IDM to perform fully its duties under the Agreement.

8.3 MARKETING ASSISTANCE, PROVISION OF KNOW-HOW

IDM shall use its reasonable commercial efforts to provide all necessary data to reasonably
assist the Distributor in its marketing effort, including supplying the Distributor with relevant
IDM Know-How as it becomes available.

9 COOPERATION BETWEEN PARTIES

9.1 MARKETING PLANNING

The Parties will meet at least once a year to review (i) the current Business Year and (ii) to
formulate the Distributor’s Marketing Plan for the following Business Year.

9.2 INTELLECTUAL PROPERTY RIGHTS

All current and future intellectual property rights covering the Product shall remain to IDM.

As of the Date of Signature, IDM shall control and undertake the prosecution, maintenance and
enforcement of all the Product-related claiming patents and Trademark valid in the Territory and
shall be responsible for all costs and expenses in connection with the prosecution and maintenance
of all the Product-related claiming patents valid in the Territory. Should it be requested by any
patent office, CL will provide where they exist necessary signature, information or documents upon
request of IDM.

9.3 IDM’s PATENT OBLIGATIONS

	(a)	 	IDM shall at its cost, file any Patents as soon as it has gathered together the relevant
information necessary and all pre-requisites to do so.
	 
	(b)	 	IDM, shall at its cost, use all reasonable endeavours to prosecute any Patents to grant in
the Territory and to obtain as broad a protection as is possible without jeopardising the
validity of the Patent. For procedures initiated in order to get a protection in the
Territory, IDM shall keep CL fully informed of the progress of the Patent examination and
issuance process, providing CL with one (1) annual written report and one (1) copy of every
important correspondence as it occurs.
	 
	(c)	 	Once any Patents have proceeded to grant in the Territory, IDM shall, at its cost, pay all
renewal fees and otherwise do all things necessary to maintain the validity of the Patents.
	 
	(d)	 	IDM shall be responsible, at its cost, for the defence and enforcement of the Patents in the
Territory. CL shall, at IDM’s cost, provide all reasonable assistance to IDM in any action for
the defence or enforcement of the Patents.
	 
	(e)	 	CL shall promptly inform IDM in writing upon its becoming aware of any possible third party
infringement of the Patents. IDM shall thereafter promptly bring suit against the infringer.
IDM shall keep CL fully informed of the progress of any action it takes against the infringing
party.
	 
	 	 	Subject to the Orphan Drug designation being broken or it having expired should either (a)
IDMs action against any infringer or any party challenging the validity of the Patents be
unsuccessful or (b) the terms of any final settlement reached between IDM and any infringing
party or any

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	19 / 36

	 	 	party challenging the validity of the Patents be such that, as a consequence the infringing
party or the party challenging the validity of the Patent is able to continue with its
activities, and that results in substantial competition for CL to the Product in the
Territory (i.e. a similar product to the Product manufactured using similar methods is able
to be marketed in the Indication and/or a New Indication and sold in the Territory) then the
Parties will meet and agree appropriate commercial amendments to the Agreement to reflect
the change in the market. If the Parties can not agree appropriate commercial amendments,
the Chief Executive Officers of each Party shall attempt for a period of not more than sixty
(60) days to reach an agreement. If the Chief Executive Officers can not reach an agreement
in the said sixty (60) days, the outcome shall finally be settled by an independent analysis
from a mutually agreed independent third party whose decision shall be binding upon the
Parties and cost of such independent analysis shall be paid entirely by the party that the
independent third party rules against.

9.4 IDM’s ORPHAN DRUG DESIGNATION OBLIGATIONS

	(a)	 	IDM shall pay all fees and perform all acts necessary to maintain for its full term the
Orphan Drug designation for the Product.
	 
	(b)	 	IDM shall defend at its cost any attempt by the Committee for Orphan Medicinal
Products to remove the Orphan Drug designation for the Product, save as where IDM has been
advised in an independent review by a Queen’s Counsel that the said defence is unlikely to
be successful.
	 
	(c)	 	IDM shall defend at its cost any attempt by a competitor to break the Orphan Drug
Designation for the Product, save as where IDM has been advised in an independent review by
a Queen’s Counsel that the said defence is unlikely to be successful.
	 
	(d)	 	In the event that following its review, the Committee for Orphan Medicinal Products
removes the Orphan Drug designation from the Product or a competitor successfully breaks
the Orphan Drug designation then the Parties agree to meet and discuss in good faith the
commercial impact on the Product and if necessary amend the commercial terms of the
Agreement to reflect the change in market conditions. If the Parties can not agree
appropriate commercial amendments, the Chief Executive Officers of each Party shall attempt
for a period of not more than sixty (60) days to reach an agreement. If the Chief Executive
Officers can not reach an agreement in the said sixty (60) days, the outcome shall finally
be settled by an independent analysis from a mutually agreed independent third party whose
decision shall be binding upon the Parties and cost of such independent analysis shall be
paid entirely by the party that the independent third party rules against.

10 FORECASTS AND ORDERS

10.1 FORECASTS

	(a)	 	IDM shall sell to the Distributor and the Distributor shall purchase the Products from IDM
under the conditions set forth herein and the applicable Standard Operating Procedures. IDM
will be responsible for the GMP manufacturing of the Product and all related expenses.
	 
	(b)	 	The Distributor shall order the Products from IDM in such quantities as are necessary to meet
the demand for the Products in the Territory and maintain the permanent inventory stated in
Article 7.2 (d). The Distributor’s orders shall be based on sales and purchase forecasts
developed by the Distributor in good faith and in consultation with IDM and using the best
available information, and communicated at the end of every quarter in writing to IDM.

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	20 / 36

	(c)	 	The sales and purchase forecasts shall cover a minimum period of twelve (12) months and shall
be updated every quarter on a rolling twelve (12) month basis. The first three (3) months of
each purchase forecast shall be considered as firm purchase orders. The first sales and
purchase forecast shall be provided twelve (12) months prior to the anticipated grant of the
Marketing Approval and the first quarter that shall become binding will be the first full
quarter after the Marketing Approval has been granted.
	 
	(d)	 	Firm purchase orders shall not deviate by more than twenty five percent (25%) from the
relevant quarterly forecasts detailed in Article 10.1 (c) for the Product for Delivery during
the relevant period. If any increase is superior to twenty five percent (25%) from said
quarterly forecasts, the Parties shall negotiate the best possible way to fulfil the
Distributor needs. However, in no case shall IDM be forced to deliver the part exceeding
twenty five percent (25%).

10.2 ORDERS

The Distributor shall provide IDM with its actual written purchase orders at least ninety (90)
days before the requested date of Delivery of the Product.

11 PRICE OF PRODUCT

11.1 CONDITION PRECEDENT

11.1.1 Public Price

As a condition precedent to IDM’s obligation to deliver any Product under this Agreement, the
Authorities shall have granted, accepted or authorised a Public Price for each presentation of the
Product as set forth in Schedule A.

CL shall undertake commercially reasonable efforts to obtain the highest Public Price on the
Product from the Authorities in the Territory

11.1.2 No material adverse change

At the date of the grant, acceptance or authorisation of the Public Price in accordance with
Article 11.1.1 above and since the Date of Signature (i) no change in the assets, liabilities,
financial condition, operations, business or prospects of IDM or Distributor shall have occurred,
which could have a material adverse effect on its ability to meet its obligations under this
Agreement; and (ii) no regulatory or legal restrictions or requirements shall have been imposed
which are inconsistent in any material respect with the transactions contemplated by this
Agreement. If any of (i) or (ii) happened, the Parties shall negotiate to evaluate the best
possible option to perform the Agreement. Should they not agree within two (2) months from the date
of the grant, acceptance or authorisation of the Public Price that Article 22.2 shall apply.

11.2 TRANSFER PRICE OF PRODUCT

The Transfer Price due to IDM by the Distributor for the Product is [...***...].

In order to compensate the Distributor for credits, IDM shall on a forecast quarterly basis, supply
free of charge Product to the Distributor equal to the amount of Product, which the Distributor can
demonstrate through documentary evidence to require crediting in the preceding forecast quarter,
provided that IDM’s obligation to supply free of charge Product for this purpose shall never exceed
[...***...] of Net Sales for the relevant forecast quarter.

IDM will deliver Product to CL along with an invoice. Payment of all invoices related to the
forecast quarter shall be due sixty (60) days after the end of the forecast quarter during which
the Delivery occurred.

			
	 	 	 
	IDM Initial
	 	CL Initial
	
	 	

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested

under 17 C.F.R. §§ 200.80(b)(4) and

240.24b-2(b)(1)

 

 

			
	May 10, 2005
	 	21 / 36

11.3 ROYALTIES

Distributor shall pay to IDM:

	(a)	 	a royalty of [...***...] of Net Sales up to the achievement of [...***...] of cumulative Net
Sales in the Territory and thereafter;
	 
	(b)	 	a royalty of [...***...] of Net Sales for the remainder of the term of the Agreement.

11.4 ROYALTY PAYMENT AND RECONCILIATION

Within three (3) business days preceding the end of each forecast quarter, the Distributor will
provide IDM with a reasoned estimate of its Net Sales for said forecast quarter. For that period,
IDM shall send the Distributor a royalty invoice based on this estimated Net Sales figure for the
applicable percentage of Net Sales as set forth above minus the amount invoiced separately
according to Article 11.2 above. The Net Sales figure calculated from the applicable percentage of
Net Sales as set forth in Article 11.3 above and used for reconciliation purposes shall not be less
than the Transfer Price. Payment of said invoice shall be due sixty (60) days after the invoice
date. Reconciliation for the last three (3) business days shall occur on the next forecast quarter.

11.5 CURRENCY AND EXCHANGE RATES

All IDM invoices will be issued in Euro. Where relevant and for the relevant quarter for which
invoice is due, Net Sales shall be converted from local currency to euros at the average rate
published by the European Central Bank covering the said relevant quarter.

11.6 PRICE REVISION

11.6.1 Following Cost of Goods changes

IDM may review the Transfer Price to take account of any increased cost of production and raw
material costs provided that such review shall not occur more than once during any period of twelve
(12) months during the term of this Agreement, provided the percentage increase in price does not
exceed the percentage increase published by the US Bureau of Labor Statistics (producer price
indexes — finished goods except foods and energy -
http://www.bls.qov/news.release/ppi.nr0.htm) for the preceding twelve (12) months and the
increase is shared in proportion to the royalty payment detailed in Article 11.3 between the
Parties. IDM shall provide written evidence to CL of such increases in the costs of production and
raw materials. In the event that IDM proposes a percentage increase in the price that exceeds the
percentage increase published by the US Bureau of Labor Statistics (producer price indexes -
finished goods except foods and energy — http://www.bls.qov/news.release/ppi.nr0.htm) for
the preceding twelve (12) months due to an exceptional increase in cost of production and raw
material costs, the Parties shall meet to discuss that exceptional increase, the reasons for it and
ways in which that increase might be offset including, but not limited to, for example, alternative
sources of supply of any raw material in question. If, after going through that process, the
Parties find that the increased costs cannot be fully offset, they shall agree an increase in the
price that shares in proportion to the royalty payment detailed in Article 11.3 between the Parties
the burden of that exceptional increase in cost. In any event, a change in the Transfer Price may
not be applied within the first twenty four (24) months of the Effective date.

11.6.2 Following commercial amendments

For the sake of clarity the Transfer Price can be renegotiated subject to the conditions in
Articles 3.4.1, 9.3, 9.4 and 16.2

12 DELIVERY OF PRODUCT

	(a)	 	Save as set out in Article 12 (b) IDM will ship the Product to CL at its own expense.

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested

under 17 C.F.R. §§ 200.80(b)(4) and

240.24b-2(b)(1)

 

 

			
	May 10, 2005
	 	22 / 36

Shipments of Product which are for less than twenty four (24) Products, shall be at Distributor’s
costs. As an exception to the definition inserted in Article 1, Delivery for the purpose of this
Article 12 (b) shall mean delivery of Product EXW (2000 ICC Incoterms).

	(b)	 	Shipment of the Product to the Distributor’s warehouse from IDM Site shall be made by any
means of transportation determined by IDM.
	 
	(c)	 	The Parties agree that risk and title to the Product shall remain with IDM until Delivery to
the Distributor whereupon risk and title shall pass to Distributor.

13 RECORDS

13.1 RECORDS

The Distributor shall keep complete and accurate records in connection with the payments
provided for under this Agreement. IDM shall have the right to nominate an independent firm of
certified public accountants who shall have access to the books and records of the Distributor
during reasonable business hours and on reasonable notice and not more than once in each Business
Year for the purpose of verifying any amounts payable under this Agreement. Such audit to be
restricted to the two (2) prior Business Year provided that no single Business Year is audited more
than once. The fees and expenses of the accountants performing such verification shall be borne by
IDM unless such accountants discover a material (i.e. greater than five percent (5%)) discrepancy
in the payments made to IDM by the Distributor, in which event the Distributor shall immediately
make good the discrepancy and the fees and expenses of the accountants shall be borne by the
Distributor.

13.2 LATE PAYMENTS

In case of late payment, the Distributor shall pay an interest (on a daily basis) on overdue
payment at a rate equal to twelve (12) months EURIBOR plus three (3) percent from the date payment
becomes due until receipt of the payment in full by IDM or, if lower, at the highest rate permitted
by mandatory provisions of local law in the Territory.

13.3 GUARANTEE

In case of late payment or identified risk of late payment IDM may, at its discretion. require
from the Distributor financial guarantees which it considers as appropriate.

14 STORAGE — INVENTORY — RETURNS

14.1 STORAGE

The Distributor shall store the Product in accordance with the Standard Operating Procedures
shown in Schedule B.

14.2 RETURN OF PRODUCT

Return of Product to IDM is authorised only for defective Product or for Product recall. The
Distributor shall return Product in accordance with the Standard Operating Procedures shown in
Schedule B.

15 QUALITY

15.1 QUALITY CONTROL

Each Party shall respect the Standard Operating Procedures and allow representatives from the
other
Party to enter any of its premises or third party premises associated with the Product manufacture,
storage, release and handling on reasonable notice and no more than once a year during business
hours to inspect Product or the manufacture, storage and handling of Product or Product-related
promotional literature in its possession.

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	23 / 36

15.2 SUSPENSION OF DISTRIBUTION

If requested by IDM as a result of a problem with the quality of the Product or by the EMEA or
the Authorities, the Distributor shall immediately suspend sales and distribution of the Product.
If IDM so requests CL to cease distribution the Minimum Annual Quota shall not apply for that
Business Year.

15.3 PRODUCT RECALL

IDM shall promptly notify the Distributor of any recalls initiated by IDM or required or
advised by the EMEA or the Authorities in respect of the Product. Upon receipt of notice of such
recall from IDM, the Distributor shall immediately notify its affected customers and clients, in
accordance with Schedule B. Except for what is stated in Article 19.1 below, IDM shall be
responsible for the mailing, shipping and reasonable administrative expenses incurred by the
Distributor in connection with such recall as well as the cost of replacement of Products for the
Distributor and its customers.

16 TRADEMARKS

16.1 USE OF TRADEMARKS

	(a)	 	The Distributor acknowledges and agrees that the Trademarks are the sole and exclusive
property of IDM and/or its Affiliates. The Distributor recognizes the validity of the title of
IDM in and to the Trademarks used in any country in connection with the Products, whether
registered or not. The Distributor further acknowledges the distinctiveness (whether inherent
or acquired), validity, originality, and value of the Trademarks and the goodwill attached to
the business in goods and services on and in relation to which the Trademarks are used, and
the Distributor shall not raise or cause to be raised any question concerning, or objections
to, the distinctiveness, validity, originality, or value of, or goodwill in, the Trademarks,
the right of IDM to register same in any country, any registrations thereof, or the right or
title of IDM, thereto, on any grounds whatsoever.
	 
	(b)	 	The Distributor shall not do or authorise any act or thing which will in any way impair the
rights of IDM and/or its Affiliates in and to the Trademarks nor represent that it has any
right or title to the ownership of the Trademarks or their registration. The Distributor shall
not use any other trademarks than the Trademarks in connection with its distribution of the
Product and shall not register any of the Trademarks for its own account or use a mark, name
or logo that is confusingly similar to the Trademarks to identify any other product
manufactured, distributed or sold by the Distributor in or outside the Territory.
	 
	(c)	 	The license to use the Trademarks in the Territory, granted in Article 2.1 (b), is made
provided that such use shall be:

	 	(i)	 	limited to the term of this Agreement;
	 
	 	(ii)	 	limited to use on the labels and packaging for the Products and/or other printed
material related to the sale and promotion of the Products, as approved in advance by
IDM;
	 
	 	( iii)	 	solely in connection with the registration, promotion, marketing, sale and
distribution of the Product in the Territory; and
	 
	 	(iv)	 	subject to the following conditions destined to protect the goodwill associated with the
Trademarks and to prevent the deception of the public :

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

			
	May 10, 2005
	 	24 / 36

	 	(α)	 	such use shall be in accordance with the shape, form and colour of
the Trademarks as communicated or authorized by IDM in writing;
	 
	 	(β)	 	such use shall clearly indicate that the Trademarks are owned by IDM,
e.g., by using the appropriate TM / ® symbol and by stating that the
Trademarks are owned by IDM;
	 
	 	(X)	 	should there be a discrepancy from the standards,
specifications or instructions provided by IDM the Distributor shall arrange
to satisfaction of IDM for correction of each and every discrepancy;
	 
	 	(δ)	 	the Distributor shall not otherwise at any time use the
Trademarks or the IDM name and/or logo or any trademark or trade name owned
by IDM and/or its Affiliates, except in accordance with the written
instructions of IDM.

	(d)	 	All rights arising from the use of the Trademarks in the Territory shall inure solely to
the benefit of IDM and/or its Affiliates, it being understood that nothing contained herein
shall give the Distributor any right or interest in the Trademarks. IDM will pay for filing
and maintenance of the Trademarks in the Territory.
	 
	(e)	 	Upon expiration or termination for any reason of the license granted, the Distributor
acknowledges and agrees that:

	 	(i)	 	neither the Distributor nor any of its successors or assignees will take any
action which implies that it is or was an Affiliate, subsidiary, division or the like
of IDM;
	 
	 	(ii)	 	it shall immediately discontinue and forever desist from any and all use of the
Trademarks, subject to Article 17.4 below;
	 
	 	(iii)	 	it shall deliver to IDM or destroy, at IDM’s cost, all printed matter bearing
the Trademarks, remove all signs bearing the Trademarks and take whatever action is
necessary to effect discontinuance of use of the Trademarks;
	 
	 	(iv)	 	it shall not seek to register the Trademarks in any country; and
	 
	 	(v)	 	it shall not make any use, or seek any type of registration of any trade name,
business or corporate name or any trademark or service mark which in whole or in part
either substantially resembles or is confusingly similar to the Trademarks.

16.2 PRODUCT MARK INFRINGEMENT

	(a)	 	The Distributor shall notify IDM immediately upon it’s becoming aware of any actual or
threatened infringement of the Product Marks within the Territory or any claims or actions
coming to the Distributor’s attention arising out of the use of the Product Marks
associated with the Products.
	 
	(b)	 	The Distributor shall provide reasonable assistance to IDM and/or its Affiliates in any
action to protect the Product Marks.
	 
	(c)	 	Any cost incurred by the Distributor at the request of IDM in connection with any legal
action relating to the enforcement or defence of the Product Marks shall be borne by IDM.
	 
	(d)	 	In the event that a third party infringes the Product Marks in the Territory, IDM shall
have the right, but not the obligation, to bring legal action to restrain such infringement
and to recover damages. If IDM elects not to bring any such legal action IDM may authorise
the Distributor to do so in its own name and at its own expense but solely for its own
benefit. IDM’s failure to take legal action hereunder shall not constitute a waiver or
amendment of any other right of IDM hereunder.

			
	 	 	 
	IDM Initial
	 	CL Initial

 

 

	 	 	 
	May 10, 2005

	 	25/36

	 	(e)	 	If, following a decision by IDM to undertake legal action, (i) IDMs action against
any infringer or any party challenging the validity of the Product Marks is
unsuccessful and allows the infringing party or the party challenging the validity of the
Product Marks to use a colourably similar mark in the Territory or (ii) the terms of any
final settlement reached between IDM and any infringing party or any party challenging the
validity of the Trademark allows the infringing party or the party challenging the validity
of the Product Marks to use a colourably similar mark in the Territory or, if, following a
decision by IDM not to undertake legal action in response to a written opinion from a
Queen’s Counsel confirming that such action is unlikely to succeed and which allows the
infringing party or the party challenging the validity of the Product Marks to use a
colourably similar mark in the Territory, then the Parties will meet and agree appropriate
commercial amendments to the Agreement to reflect the change in the market. If the Parties
can not agree appropriate commercial amendments, the Chief Executive Officers of each Party
shall attempt for a period of not more than sixty (60) days to reach an agreement. If the
Chief Executive Officers can not reach an agreement in the said sixty (60) days, the
outcome shall finally be settled by an independent analysis from a mutually agreed
independent third party whose decision shall be binding upon the Parties and cost of such
independent analysis shall be paid entirely by the Party that the independent third party
rules against.
	 
	 	(e)	 	In the event that either (i) IDM does not seek an opinion from a Queens Counsel and opts not
to defend against any infringer or any party challenging the validity of the Product Marks or
(ii) opts not to defend against any infringer or any party challenging the validity of the
Product Marks following a recommendation from a Queens Counsel that a defence would be
worthwhile and as a consequence allows the infringing party or the party challenging the
validity of the Product Marks to use a colourably similar mark in the Territory then the
royalty rate payable by CL herein under shall be immediately lowered to [...***...].

	16.3	 	MAINTENANCE OF THE TRADEMARKS

IDM shall seek and maintain, or shall cause its Affiliates to seek and maintain, the
registration of the Trademarks in the Territory throughout the term of this Agreement, subject to
the limitation of Article 16.4 below.

	16.4	 	INACTIVE OR ABANDONED TRADEMARKS

IDM and/or its Affiliates shall have no obligation to defend and maintain any Trademark that
IDM considers, in its sole discretion, inactive and/or abandoned.

	17	 	TERM AND TERMINATION OF THE AGREEMENT
	 
	17.1	 	TERM OF THE AGREEMENT

This Agreement shall take effect on the Date of Signature and shall, unless terminated in
accordance with Article 17.2, remain in force for the Initial Term.

At least six (6) months prior to the end of the Initial Term, the Parties will meet to discuss, in
good faith, the possibility and the terms and conditions of renewing the Agreement.

	17.2	 	TERMINATION

	(a)	 	IDM may terminate this agreement by sixty (60) day prior written notice (which includes the
timelines detailed in (i) and (ii) below), if CL, having received written notice setting forth
any details of any alleged breach of the following Articles of this Agreement, fails to remedy
such default within the time frames set forth below;

	 	 	 
	IDM Initial

	 	CL Initial

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested

under 17 C.F.R. §§
200.80(b)(4) and

240.24b-2(b)(1)

 

 

	 	 	 
	May 10, 2005

	 	26/36

	 	(i)	 	late payment for the Product not remedied within twenty (20) business days
from receipt of notification;
	 
	 	(ii)	 	breach of Articles 3.1 (a), 7.1 (h), 7.2 (h) or 7.4 (b) that are not remedied
within twenty (20) business days from receipt of notification;
	 
	 	(iii)	 	the Distributor fails to commence to actively promote, market, distribute and
sell the Product in the Territory within three (3) months of the start of the Effective
Date.

	(b)	 	The Agreement may be terminated by the Distributor by one (1) month’s written notice in the
event that Marketing Approval have not been granted within 30 (thirty) months from the Date of
Signature.
	 
	(c)	 	Subject to Article 22.2 the Agreement may be terminated by either Party, immediately by
written notice in the event:

	 	(i)	 	that the other Party filing in any court or agency pursuant to any statute or
regulation, a petition in bankruptcy or insolvency or for reorganization of the Party
or of its assets, or if the other Party proposes a written agreement of composition or
extension of its debts, or if the other Party shall be served with an involuntary
petition against it, filed in any insolvency proceeding, and such petition shall not be
dismissed with sixty (60) days after the filing thereof, or if the other Party shall
propose or be a party to any dissolution or liquidation, or if the other Party shall
make an assignment for the benefit of creditors;

	 	(ii)	 	of failure by the other Party to remedy its default (other than the defaults
listed in Article 17.2 (a)) within (60) days after receipt of a written request to
remedy the default from the terminating Party.

	17.3	 	CHANGE OF CONTROL / ASSIGNMENT

The Agreement may be terminated immediately in writing in the event of a change of control of
the Distributor, i.e. acquisition, directly or indirectly, by any third party, of any
beneficial interest, voting rights or power to direct or cause the direction of the management
and/or policies of the Distributor, whether through the ownership of voting securities, by contract
or otherwise, where such party manufactures or sells a Competitive Product and said Competitive
Product remains in the portfolio of the combined entity following portfolio review. If six (6)
months after the Distributor informed IDM of the change of control a decision has not been made
regarding whether the Competitive Product should remain in the combined portfolio the Chief
Executive Officers of each Party shall attempt for a period of not more than sixty (60) days to
reach an agreement on the situation. If the Chief Executive Officers can not agree appropriate
commercial amendments in the said sixty (60) days, IDM shall be entitled to terminate this
Agreement according to Article 17.2 (c) (ii).

IDM acknowledges that this Agreement is being entered into by the Irish branch of CL. In the near
future it is intended to incorporate the Irish branch as a separate legal entity under common
ownership with CL. IDM agrees to the assignment of the rights, obligations, benefits, and burdens
of this agreement from CL to the Irish affiliated company under common ownership with CL at the
time that Irish branch is incorporated as a separate legal entity.

Save as set forth above neither this Agreement nor any interest hereunder shall be assignable by
either Party without the written consent of the other; provided, however, that each Party may
assign this Agreement without obtaining the other Party’s consent to any of its Affiliates or to
any other person with which such Party may merge, consolidate or transfer all or substantially all
of such Party’s assets related to the Product. All rights and obligations under this Agreement and
the licenses herein granted shall be binding upon and inure to the benefit of the successors in
interest of the respective Parties. Any assignment in violation of the foregoing shall be null and
void.

	17.4	 	CONSEQUENCES OF TERMINATION

	 	 	 
	IDM Initial

	 	CL Initial

 

 

	 	 	 
	May 10, 2005

	 	27/36

(Upon expiration or termination of this Agreement for any reason, the Distributor shall:

	(a)	 	work together with IDM, and, if applicable, another distributor chosen by IDM from the moment
that the notice of termination has been given, on transferring and/or assigning, without delay
and free of charge, to IDM or its designee any and all other licenses, approvals, permits and
other rights the Distributor may have acquired under this agreement which may be in the name
of the Distributor relating to the Product in the Territory (i.e. the Acquired Rights ). To
the extent assignment or transfer of the Acquired Rights is not permitted under local law in
the Territory, the Distributor shall co-operate, upon IDM’s option, in their cancellation or
abandonment or in their reissuance to IDM or its qualified designee. The Distributor shall
also deliver to IDM or its nominee and cease to use IDM Know-How;

	(b)	 	the Distributor shall immediately cease to use and make no further use in the Territory of
the Trademarks and/or any name or marks confusingly similar to the Trademarks subject to what
is set forth below;

	(c)	 	pay immediately to IDM all sums owed to IDM;

	(d)	 	deliver to IDM an accurate and complete customer list;

	(e)	 	not prevent IDM, or another distributor chosen by IDM, from promoting and selling Product to
customers, nor be entitled to any compensation in respect of such sales;

	(f)	 	be allowed to sell through any remaining stock of the Product or, at IDM’s option, destroy or
transfer to IDM, the Distributor’s inventory of Products against a refund at the Transfer
Price by IDM provided that such Products has been stored in accordance with IDM’s transport
and storage procedure. The ancillary costs will not be refunded by IDM to Distributor in case
of termination by IDM pursuant to Articles 17.2 (a), 17.2 (b) or 17.2 (c);

and, at IDM’s written option:

	(g)	 	be allowed, should it so desire, to continue to temporarily promote (or co-promote) the
Product to customers (or part of them) until requested to stop by IDM with one (1) months
written notice. For the avoidance of doubt should IDM desire Distributor to continue promotion
and Distributor wish to act in that capacity beyond termination or expiration then the terms
of this agreement shall continue to apply until the end of the notice period contained in this
Article.

	18	 	CONSEQUENTIAL LOSS — INSURANCE
	 
	18.1	 	CONSEQUENTIAL LOSS

Neither Party shall be liable to the other under this Agreement, in tort or otherwise for
special, indirect, punitive, consequential or incidental damages. For the sake of clarity nothing
herein shall limit the liability of either Party to third parties in respect of claims for death or
personal injury arising from that party’s negligence.

	18.2	 	INSURANCE

Each Party shall:

	(a)	 	obtain and maintain in the Territory, during the term of the Agreement, commercial general
liability insurance, including product liability insurance that covers their respective
obligations under this Agreement with coverage limits of not less than the local currency
equivalent of one million euros (1,000,000 €) per occurrence. Each insurance policy shall
require the insurance carrier to provide the other Party with no less than thirty (30) days
written notice of any change in the terms of the coverage of the policy or of its
cancellation;

 

 

	 	 	 
	May 10, 2005

	 	28/36

	(b)	 	not cancel or reduce the level of coverage of such liability insurance without the
other’s written approval;

	(c)	 	provide to the other on first demand with a certificate of insurance verifying that such
insurance is in force.

	19	 	INDEMNIFICATION

	19.1	 	INDEMNIFICATION BY THE DISTRIBUTOR

Subject to the provisions of Articles 19.2 and 19.3, the Distributor shall defend, indemnify
and hold harmless IDM and its Affiliates and their respective directors, officers, agents and
employees (i.e. IDM’s Representatives) from and against any and all losses, liabilities, claims,
damages, penalties, fines, costs and expenses reasonably and properly incurred (including
reasonable legal fees and other litigation costs, regardless of outcome) and arising out of any
third party claims or any voluntary or mandatory recall of the Product to the extent caused by:

	(a)	 	the storage, shipment, use, handling, promotion, marketing, distribution and sale of the
Product by the Distributor, its Affiliates and their respective directors, officers, agents
and employees (i.e. Distributor’s Representatives), or any other non-IDM party after Delivery;

	(b)	 	any claim or failure by the Distributor or Distributor’s Representatives to comply with
governmental requirements relating to the Product including, but not limited to, the
Distributor’s or Distributor’s Representatives’ failure to report adverse events;

	(c)	 	the Distributor’s or Distributor’s Representatives’ errors, wilful misconducts, grossly
negligent acts or omissions in connection with the Product or;

	(d)	 	the Distributor’s or Distributor’s Representatives’ violation of the Distributor’s
obligations under this Agreement.

This provision shall survive the expiration or termination of this Agreement.

	19.2	 	INDEMNIFICATION BY IDM

Subject to the provisions of Articles 18.2 (a), 19.1 and 19.3, IDM shall defend, indemnify and
hold harmless the Distributor and its Affiliates and their respective directors, officers, agents
and employees (i.e. Distributor’s Representatives) from and against any and all losses,
liabilities, claims, damages, penalties, fines, costs and expenses reasonable and properly incurred
(including reasonable legal fees and other litigation costs regardless of outcome) arising as a
result of any third party claims or mandatory or voluntary recall of the Product to the extent
caused by:

	(a)	 	failure of the Product to conform to the Product Specifications during its shelf life or a
failure to comply with GMP in the manufacture, storage and transport of the Product or any
other failure pertaining to the manufacture of the Product before Delivery;
	 
	(b)	 	any latent or inherent defect in the Product;
	 
	(c)	 	any wilful act or gross negligence of IDM or IDM’s Representatives in relation to the
Product; or;
	 
	(d)	 	breach by IDM or IDM’s Representatives of IDM’s obligations under this Agreement, provided,
however, that IDM shall have no obligation to indemnify or hold the Distributor harmless when
or if the Distributor, Distributor’s Representatives, customers or transferees of the Product
have been negligent whether in storing or handling the Product or otherwise;

 

 

	 	 	 
	May 10, 2005

	 	29/36

	(e)	 	any claim of failure by IDM or IDM’s Representatives to comply with governmental
requirements relating to the Product including, but not limited to, IDM’s or IDM’s
Representatives’ failure to report adverse events;
	 
	(f)	 	IDM’s or IDM’s Representatives violation of IDM’s obligations under this Agreement;

	 
	(g)	 	sale of the Product in the Territory infringes the intellectual property rights of that third
party. This provision shall survive the expiration or termination of this Agreement.

	19.3	 	INDEMNITY PROCEDURE

Any Party seeking to be indemnified hereunder (i.e. the Indemnified Party) shall notify the
other Party (i.e. the Indemnifying Party) in writing promptly, but no later than fifteen (15) days
after becoming aware of any actual or potential claim in respect of which indemnification may be
sought.

	19.4	 	DEFENCE OF CLAIM

Upon receipt of notice the Indemnifying Party shall have the right, but not the obligation, to
defend against, control the defence of, and settle any such claim. If the Indemnifying Party elects
to assume the defence of any claim, the Indemnifying Party shall no longer be liable for any legal
or other expense subsequently incurred by the Indemnified Party in connection with the defence. The
Indemnified Party shall co-operate with the Indemnifying Party in the defence of any claim and
shall be entitled to participate in the defence of such action provided, however, the decisions of
counsel for the Indemnifying Party shall be controlling and the Indemnified Party shall be
responsible for the expenses of its own counsel, if any. There shall be no settlements, whether
agreed to in court or out of court, without the prior written consent of the Indemnifying Party.

	20	 	ACTIONS OF COMPETITORS, LITIGATION

	(a)	 	The Distributor undertakes to monitor the actions in the Territory of any direct competitor
of IDM and/or the Product and shall promptly inform IDM if it believes that such competitor is
unfairly disparaging the Product or infringing any national or supranational laws or
regulations relating to the sale or distribution of pharmaceutical products or the promotion,
advertising or sale of such products.

	(b)	 	The Parties shall discuss and agree upon a course of action to deal with a competitor’s
illegal or unfair action which may include, if agreed by both Parties, bringing any legal
proceedings or other appropriate actions before any competent court Authority or professional
body in the Territory subject to the Parties obtaining a written opinion from a Queen’s
Counsel confirming that such action is likely to succeed.

	21	 	CONFIDENTIALITY
	 
	21.1	 	CONFIDENTIAL INFORMATION

The recipient of any Confidential Information shall receive and keep all Confidential
Information in complete confidence and hereby covenants not to use any Confidential Information
except for the purposes of this Agreement or disclose or make such Confidential Information
available to third parties except:

	(a)	 	to its employees and responsible sub-contractors or agents who require it for the purposes of
this Agreement and who are bound to the recipient by like obligations of confidentiality;

	(b)	 	for the purpose of obtaining and maintaining any necessary Regulatory Approvals;
	 
	(c)	 	to the extent that the disclosing Party may agree in writing;

 

 

	 	 	 
	May 10, 2005

	 	30/36

	(d)	 	to the extent that such can be demonstrated by written records to be known to the
recipient from a source other than discloser or its Affiliates at the time of receipt from
discloser or its Affiliates hereunder;

	(e)	 	to the extent that such is a matter of public knowledge at the time of disclosure hereunder
or becomes a matter of public knowledge other than by breach of this Agreement by the
recipient, its employees or anyone that received Confidential Information from the recipient.

	21.2	 	PRIOR CONFIDENTIALITY AGREEMENT

Confidential Information disclosed by IDM to the Distributor prior to the Date of Signature
under the Confidentiality Agreement shall be governed by such Confidentiality Agreement until its
expiration and thereafter shall be treated as Confidential Information under Article 21.1
notwithstanding the expiration of the prior Confidentiality Agreement. All Confidential Information
disclosed by IDM to the Distributor after the Date of Signature shall be governed by this Article
21.

	22	 	GOVERNING LAW — DISPUTES
	 
	22.1	 	GOVERNING LAW

This Agreement shall be governed by, and construed in accordance with the laws of the
defendant, without regard to any provisions relating to the conflict of jurisdictional legal
requirements.

	22.2	 	DISPUTES
	 
	22.2.1	 	Mediation

Prior to engaging in any formal dispute resolution with respect to any dispute, controversy or
claim arising out of or in relation to the License Agreement or the breach, termination or
invalidity thereof (each, a “Dispute”), the Chief Executive Officers of the respective
Parties or their authorized designees shall attempt for a period not less than sixty (60) days to
resolve such Dispute. Any Dispute that cannot be settled amicably by agreement of the Parties
pursuant to the preceding sentence, shall be finally settled by binding arbitration.

	22.2.2	 	Arbitration

Arbitration shall be held in English in accordance with the rules of CEPANI (Centre Belge pour
l’Etude et la Pratique de l’Arbitrage National et International) by a panel of three arbitrators
appointed in accordance with such rules. The place of arbitration shall be Brussels. Language of
arbitration shall be English.

The arbitrators shall be appointed by agreement between the Parties or failing agreement within a
period of twenty one (21) business days shall be appointed at the request of any Party by the
Secretary-General for the time being of CEPANI. So far as possible, the decision of the arbitrators
shall be given within twenty one (21) business days from the decision to report to arbitration of
their appointment and shall be final and binding on the Parties who renounce any right of appeal
against such arbitration award.

	23	 	FORCE MAJEURE

Any violation of this Agreement resulting from an event of force majeure, such as riot, boycott,
strike, flood, act of God, act of war or terrorism, regulations or laws of any government shall not
be considered a breach of this Agreement, provided that the Party affected thereby uses its best
efforts to remedy the situation. In the event any violation of this Agreement, as a result of an
event of force majeure, continues for more than three (3) months, the Party not affected
thereby shall have the right to terminate this Agreement with immediate effect by written notice
sent to the other Party.

 

 

	 	 	 
	May 10, 2005

	 	31/36

	24	 	REPRESENTATIONS AND WARRANTIES

	24.1	 	REPRESENTATIONS AND WARRANTIES OF IDM

IDM represents and warrants that as of the date hereof:

	24.1.1	 	Organization and authority

IDM is duly organized, validly existing and in good standing under the laws of France and have
all necessary power and authority to enter into this Agreement, to carry out its obligations
hereunder and to consummate the transactions contemplated hereby. The execution and delivery of
this Agreement by iDM, the performance by it of its obligations hereunder and the consummation by
it of the transactions contemplated hereby have been duly authorized by all requisite action on its
part. This Agreement has been duly executed and delivered by IDM, and (assuming due authorization,
execution and delivery by the other person signatory hereto) this Agreement constitutes a legal,
valid and binding obligation of IDM enforceable against it in accordance with its terms.

	24.1.2	 	No conflict

The execution, delivery and performance of this Agreement by IDM does not and will not (i)
violate, conflict with or result in the breach of any provision of its Certificate of Incorporation
or By-laws, (ii) conflict with or violate any law, governmental regulation or governmental order
applicable to IDM or any of its assets, properties or businesses or (iii) conflict with, result in
any breach of, constitute a default (or event which with the giving of notice or lapse of time, or
both, would become a default) under, require any consent under, or give to others any rights
pursuant to, any contract, agreement or arrangement by which IDM is bound; except to the extent
that any conflict under (ii) or (iii) above would not prevent or materially delay the consummation
of the transactions contemplated by this Agreement. Without limiting the generality of the
foregoing, IDM’s rights under the terms of the agreement signed between Ciba-Geigy and TherAtid,
Inc. (TherAtid, Inc merged with Jenner Technologies Corporation in 1996, which became Jenner
Biotherapies Inc., holder of the Product rights. Those rights were acquired by IDM in 2003) and
effective since April 4, 1996 remain valid, IDM to the best of its knowledge as of the Date of
Signature is not in breach of any of the terms of that agreement, IDM’s rights under that agreement
remain exclusive and any consents under that agreement necessary to effect the grant of rights to
the Distributor have been obtained.

	24.1.3	 	Ownership

To the knowledge of IDM, IDM is either (i) the owner of the entire right, title and interest in
and to the Product and Trademarks in the Territory or (ii) has been granted a license thereof and
has the right to grant to CL the rights granted herein. There are no further rights or intellectual
property rights under which the Distributor would require a license to be able to market, sell,
promote, or import the Product in the Territory.

	24.1.4	 	Enforceability

To the knowledge of IDM, the Product, Patents and Trademarks have not been adjudged invalid or
unenforceable in whole or part in the Territory.

	24.1.5	 	Actions

To the knowledge of IDM, no actions have been asserted or are pending, nor, to the knowledge of
IDM, has any such action been threatened, against IDM challenging or seeking to deny or restrict
the use by IDM of any of the Product or Trademarks. No IDM Site is subject to any investigation or
sanction from any Authority. IDM has not withheld material information from any submission to any
Authority regarding the Product and is not aware of any significant matter regarding the Product
that is not disclosed in any such application. IDM fully complied with GMP in the development of
the Dossier and the Product.

	24.1.6	 	No infringement

 

 

	 	 	 
	May 10, 2005

	 	32/36

To IDM’s knowledge, the use of the Product and Trademarks in connection with the business of CL
as contemplated herein does not conflict with, misappropriate, or infringe the intellectual
property rights of any third party and it has received no notices, claims or actions from any third
party of such nature.

	24.1.7	 	Warranty

To IDM’s knowledge, none of the rights licensed hereunder conflict with any license or covenant
not to sue granted by IDM to any third party.

For the sake of clarity, subject to Articles 17.2 (c) but not 22, these warranties are essential
conditions of this Agreement and if any transpire not to be wholly accurate CL shall have the right
to terminate this Agreement and seek damages from IDM. Provided that the Chief Executive Officers
of each Party have met within fifteen (15) days from having knowledge of the issue and have been
unable to resolve the issue within thirty (30) days from their initial conversation on the issue.

	24.2	 	REPRESENTATIONS AND WARRANTIES OF CL

CL represents and warrants that as of the date hereof:

	24.2.1	 	Organization and authority

CL is duly organized, validly existing and in good standing under the laws of Ireland and has
all necessary power and authority to enter into this Agreement, to carry out its obligations
hereunder and to consummate the transactions contemplated hereby. The execution and delivery of
this Agreement by CL, the performance by it of its obligations hereunder and the consummation by it
of the transactions contemplated hereby have been duly authorized by all requisite action on its
part. This Agreement has been duly executed and delivered by CL, and (assuming due authorization,
execution and delivery by the other person signatory hereto) this Agreement constitutes a legal,
valid and binding obligation of CL enforceable against it in accordance with its terms.

	24.2.2	 	No conflict

The execution, delivery and performance of this Agreement by CL does not and will not (i)
violate, conflict with or result in the breach of any provision of its Certificate of Incorporation
or By-laws, (ii) conflict with or violate any law, governmental regulation or governmental order
applicable to CL or any of its assets, properties or businesses or (iii) conflict with, result in
any breach of, constitute a default (or event which with the giving of notice or lapse of time, or
both, would become a default) under, require any consent under, or give to others any rights
pursuant to, any contract, agreement or arrangement by which CL is bound; except to the extent that
any conflict under (ii) or (iii) above would not prevent or materially delay the consummation of
the transactions contemplated by this Agreement.

For the sake of clarity, subject to Articles 17.2 (c) but not 22, these warranties are essential
conditions of this Agreement and if any transpire not to be wholly accurate IDM shall have the
right to terminate this Agreement and seek damages from CL. Provided that the Chief Executive
Officers of each Party have met within fifteen (15) days from having knowledge of the issue and
have been unable to resolve the issue within thirty (30) days from their initial conversation on
the issue.

	25	 	MISCELLANEOUS
	 
	25.1	 	ENTIRE AGREEMENT

	(a)	 	This Agreement, together with the Schedules and the Confidentiality Agreement, sets forth
the entire agreement and understanding between the Parties as to its subject matter. Except as
otherwise provided expressly herein, no modification, amendment or supplement to this
Agreement, to the Schedules or to the Confidentiality Agreement shall be effective for any
purpose unless in writing and signed by the Parties.

	 	 	 
	IDM Initial

	 	CL Initial

 

 

	 	 	 
	May 10, 2005

	 	33/36

	(b)	 	In the event of discrepancy between this Agreement and any other agreement or ancillary
document, including between this Agreement and IDM’s conditions of sale (as amended from
time to time), the provisions of this Agreement shall prevail.

	25.2	 	No WAIVER

	(a)	 	Continued supply by IDM of Products to the Distributor after the termination of this
Agreement shall not be construed as a waiver of the termination, or as a renewal of, this
Agreement.

	(b)	 	Failure by either Party hereto to enforce at any time any of the provisions of this Agreement
shall not be construed as a waiver of its rights hereunder. Any waiver of a breach of any
provision hereof shall not affect either Party’s rights in the event of any additional breach.

	25.3	 	PUBLIC ANNOUNCEMENTS

Neither Party shall make any public announcement or press release regarding the content or
signature of this Agreement without the other Party’s prior written consent other than as may be
required by law or any stock exchange rules. The Parties shall endeavour to agree the text and
content of any such public announcement or press release.

	25.4	 	NOTICES

	(a)	 	Any notice or other written communication required or permitted hereunder shall be in
writing and:

	 	(i)	 	delivered personally to the officer of the Party to whom it is directed, or

	 	(ii)	 	sent by registered mail, postage prepaid, return receipt requested (provided
that such notice or other written communication shall not be forwarded by mail if on
the date of mailing there exists an actual or imminent postal service disruption in the
city from which such communication is to be mailed or in which the address of the
recipient is found);

	 	 	 	or,
	 
	 	(iii)	 	by a confirmed telefax.

	(b)	 	All such notices shall be addressed to the Party to whom it is directed as follows:

	 	(i)	 	If to IDM, to the attention of:

	 	 	 
	by mail or personal delivery at the address set out on page 1,
	by telephone:

	 	+33 (0)1 40 09 04 11
	by fax:

	 	+33 (0)1 40 09 04 25
	with copy to:

	 	IDM France SA — Legal
Department

172 rue de Charonne

75545 PARIS Cedex 11

France

	 	(ii)	 	To the Distributor, to the attention of:

	 	 	 
	by mail or personal delivery at the address set out on page 1,
	by telephone:

	 	+ 353 1 631 9352
	by fax:

	 	+ 353 1 631 9452
	with copy to:

	 	Allistair Booth
	 

	 	Stringer Saul
	 

	 	Hanover Square
	 

	 	London W 1 S 1 HU
	 

	 	United Kingdom

 

 

			
	May 10, 2005
	 	34 / 36

	(c)	 	Any such notice or other written communication shall, if sent by registered mail as aforesaid
be effective upon receipt thereof; if given by telex or telefax, shall be effective on the
first business day after the sending thereof; and if given by personal delivery shall be
effective on the day of delivery.
	 
	(d)	 	Either Party may at any time change its address by giving notice of such change of address to
the other Party in the manner specified herein.
	 
	25.5	 	SEVERABILITY

Any provision of this Agreement part thereof that is or becomes, invalid, void or unenforceable
in any jurisdiction, shall, as to such jurisdiction, be ineffective to the extent of such
invalidity or unenforceability. The remaining provisions of this Agreement shall remain in full
force and effect, to the extent that the purpose of this Agreement is not materially altered, or
the validity or enforceability of such provisions in any other jurisdiction affected, and neither
Party hereto shall be discharged from its obligations hereunder.

The Parties agree that the invalid or unenforceable provision shall be replaced with a provision
which accomplishes, to the extent possible, the original business purpose and economic benefit of
the provision in a valid and enforceable manner, the Distributor and IDM shall endeavour in good
faith to agree upon the wording of any replacement provision.

	25.6	 	LANGUAGE

This Agreement is executed in the English language. A translation of this Agreement may be
provided for understanding; provided however, that in the event of any discrepancy or contradiction
between this original English version and any translation thereof, this original English version
shall prevail.

This Agreement shall be executed in two (2) original copies. Two (2) sets of Schedules shall be
initialled by the Parties for identification and acceptance.

	25.7	 	EXPENSES

Any costs and expenses incurred in connection with the transactions contemplated herein by
either Party prior to the Date of Signature shall be at such Party’s expense.

IN WITNESS HEREOF, the Parties have caused this Agreement to be executed by their duly authorised
representatives on the dates stated below their signatures.

	 	 	 	 	 	 	 
	On behalf of IDM	 	On behalf of CL	 	 
	Jean-Loup Romet-Lemonne	 	Mark Evans	 	 
	CEO

Date

	 	
	 	CEO

Date
	 	

			
	 	 	 
	IDM Initial
	 	CL Initial
	
	 	

 

 

			
	May 10, 2005
	 	35 / 36

26 SCHEDULES

	26.1	 	SCHEDULE A

Product Specifications: description of the current packaging of the Product is due by IDM at
least three (3) months before Effective Date and shall be attached to the Agreement as part of it.

	26.2	 	SCHEDULE B

Purchase of the Products: Standard Operating Procedures according to which the Distributor
shall purchase the Products from IDM. Such Standard Operating Procedures should be approved by the
Parties three (3) months prior Effective Date and attached to the Agreement as part of it. -
Adverse Events: The Parties’ respective pharmaco-vigilance rights and obligations and the Standard
Operating Procedures according to which the Distributor and IDM shall report the Adverse Events.
Such Standard Operating Procedures should be approved by the Parties three (3) months prior
Effective Date and attached to the Agreement as part of it. — Return of Product: Standard
Operating Procedures according to which the Distributor shall return the defective Product. Such
Standard Operating Procedures should be approved by the Parties three (3) months prior Effective
Date and attached to the Agreement as part of it. — Commercial Packaging: Standard Operating
Procedures describing the commercial packaging and the responsibilities of IDM and the Distributor
regarding commercial packaging-related issues. Such Standard Operating Procedures should be
approved by the Parties three (3) months prior Effective Date and attached to the Agreement as
part of it.

	26.3	 	SCHEDULE B-1

Standard Operating Procedures according to which the packaging of the Product is modified. It
shall be attached to the Agreement at least three (3) months prior Effective Date and be part of
it.

	26.4	 	SCHEDULE C

Minimum Annual Quotas (volume): To be agreed between the Parties and attached to the Agreement
at least three (3) months prior Effective Date and be part of it.

	26.5	 	SCHEDULE D

Distributor‘s marketing plan: due by CL at least three (3) months before Effective
Date. To be attached to this Agreement and be part of it.

 

 

			
	May 10, 2005
	 	36 / 36

27 SCHEDULE E — PATENT LIST

N-á-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylam
ide, also called muramyl tripeptide phosphatidylethanolamine (MTP-PE), was first patented and
developed by Ciba Geigy (now Novartis), then by Jenner Biotherapies, which IP rights were fully
transferred to IDM in 2003. Related patent families are the followings, expiration dates and main
claims are indicated:

[...***...]

			
	 	 	 
	IDM Initial
	 	CL Initial
	 
	 	

	 	 	 	 	 
	 

	 	*
	 	Confidential
Treatment Requested

under 17 C.F.R. §§
200.80(b)(4)
and

240.24b-2(b)(1)Exhibit 10.61

 

EXHIBIT 10.61

***Text Omitted and Filed Separately
Confidential Treatment
Requested
Under 17 C.F.R. §200.80(b)(4)
and
240.24b-2(b)(1)

AMENDED AND RESTATED IL-13 LICENSE AGREEMENT

BY AND BETWEEN THE UNDERSIGNED :

IDM, a French société anonyme with a capital of 1 569 444,60 Euros having its principal place
of business at 172 rue de Charonne, Paris (75011) and registered at the Paris Register of Trade and
Companies under B 382 632 263 represented by Jean-Loup Romet-Lemonne, President and CEO
(hereinafter, “IDM”).

AND:

SANOFI-AVENTIS, a French société anonyme with a capital of 2 791 376 578 Euros having its principal
place of business at 174, avenue de France, 75013 Paris, and registered at the Paris Register of
Trade and Companies under 395 030 844, represented by Jean-Pierre KERJOUAN, Advisor to the
President and General Counsel, and Mr. Jean-Claude MULLER, Senior Vice President Scientific and
Medical Operations Administration and Ressources (hereinafter “SANOFI-AVENTIS”);

IDM and SANOFI-AVENTIS being referred to hereinafter individually as « a Party » or jointly as «
the Parties ».

PRELIMINARY CONSIDERATIONS:

SANOFI-AVENTIS has designed and development a cytokine known as Interleukin IL-13 (or IL-13) for
which it has applied for patents and developed knowhow;

For its part, IDM has acquired and developed substantial knowhow and is the holder of patents and
relative patent applications, in particular for ex vivo cancer therapies, marketed in the form of
research kits and cell processors.

On July 13, 1999, the Parties executed an agreement, which was cancelled and replaced by an
amendment dated November 30, 2001 (hereinafter, the “IL-13 Agreement”), defining the conditions
under which SANOFI-AVENTIS granted IDM a non-exclusive license to its IL-13 Industrial Property
rights for the implementation of Phase I and II Studies on one or more IL-13 Products and the
marketing of IL-13 Research Kits in return for SANOFI-AVENTIS’ taking a stake in the capital of
IDM.

This amendment dated November 30, 2001 was further amended by amendment number 1 dated March 30,
2005, both amendments being collectively called the “IL-13 Agreement”.

The Parties also entered into a Memorandum of Agreement on July 20, 2001, pursuant to which
SANOFI-AVENTIS has, on the terms and conditions defined in such Memorandum of Agreement, a right of
first refusal to all IDM development

1

 

programs in the field of ex vivo cell therapy in humans,
whether or not they pertain to IL-13 (hereinafter, the “2001 Agreement”).

Pursuant to provisions of article 8.2 of the IL-13 Agreement and pursuant to information received
from IDM related to the change of control of IDM that will result from the announced combination
between IDM and Epimmune Inc., SANOFI-AVENTIS notified IDM of its decision to proceed with an early
exercise of BSA1 and BSA2 warrants, such notification being equivalent to exercise of Option 1 and
Option 2 (as defined in the IL-13 Agreement).

Option 1 and Option 2 being therefore exercised pursuant to provisions of the IL-13 agreement, both
Parties must therefore enter into the IL-13 License Agreement and the Amendment to the IL-13
License Agreement as annexed to the IL-13 Agreement. For the sake
of simplicity, both Parties agreed to enter into the Amended and Restated License Agreement in
order to benefit from a single document that includes all provisions of the IL-13 License Agreement
and the Amendment to the IL-13 License Agreement, after removal of several provisions that are now
obsolete.

THE PARTIES HEREBY COVENANT AS FOLLOWS:

ARTICLE 1 – DEFINITIONS

Unless otherwise specified in this IL-13 License Agreement, capitalized words used in this IL-13
License Agreement or words printed in capital letters have the meaning assigned to them in the
IL-13 Agreement.

For the benefit of this Agreement, an updated description of the IL-13 patents as of the execution
date is included in Annex 1. Such description cancels and replaces the description included in
annex 1.10 of the IL-13 Agreement.

ARTICLE 2 – LICENSE

	2.1	 	License grant
	 
	 	 	As a complement to the rights granted to IDM pursuant to the IL-13 Agreement, SANOFI-AVENTIS
hereby grants to IDM, in the Territory, a non-exclusive IL-13 Intellectual Property license
for (i) the performance of Phase III Studies for any IL-13 Development Program, for (ii) the
marketing of the IL-13 Research Kits, and (iii) for the marketing of Final IL-13 Products. A
list of the IL-13 Development Programs currently ongoing is attached in Annex 2 to this
Agreement.
	 
	2.2	 	Transfer of IL-13 Know-how and additional elements of information
	 
	 	 	The Parties hereby acknowledge that all IL-13 Know-how and additional elements of information
licensed by SANOFI-AVENTIS under this License

2

 

	 	 	Contract, have already been transferred to IDM in application of the IL-13 Agreement.
	 
	2.3	 	IL-13 supply of IDM
	 
	 	 	The conditions under which IL-13 shall be supplied to IDM are defined in Article 3 of the
IL-13 Agreement.

ARTICLE 3 – IMPLEMENTATION OF THE IL-13 DEVELOPMENT PROGRAMS

Except for SANOFI-AVENTIS IL-13 Development Programs that are governed by the 2001 Agreement, and
as a complement to IDM’s obligations under the IL-13 Agreement :

	-	 	IDM agrees to conduct, and bear all
costs related to Phase III Studies of the IL-13
Development Programs and use its best efforts to complete
these Phase III Studies in the best possible time frame
compatible with applicable legal and regulatory
requirements.
	 
	-	 	IDM shall provide SANOFI-AVENTIS
with semi-annual progress reports on the Phase III Studies
and shall inform SANOFI-AVENTIS as soon as possible of any
problem likely to have a significant negative impact on
such Phase III Studies.
	 
	-	 	Representatives of IDM and
SANOFI-AVENTIS shall meet at the request of one or the
other Party to discuss the contents of the semi-annual
progress reports on the Phase III Studies submitted by
IDM. In the course of these meetings, IDM shall provide
all additional information that SANOFI-AVENTIS might
reasonably request on the results of the Phase III
Studies, provided this additional information is available
on the date of the SANOFI-AVENTIS request and does not
require additional research or investigations over and
above those carried out by IDM.
	 
	-	 	IDM shall provide SANOFI-AVENTIS
with a summary report on the results of the Phase III
Studies conducted on one or more IL-13 Products, within
sixty (60) days following completion of these Phase III
Studies.

ARTICLE 4 – COMPENSATION 

	4.1	 	Fixed compensation
	 
	4.1.1.	 	In consideration of the rights granted by SANOFI-AVENTIS to IDM under
this Agreement for conducting Phase III Studies for any IL-13 Development Programs and the
marketing of IL-13 Research Kits, IDM shall pay SANOFI-AVENTIS a sum equal to [...***...] before
taxes. IDM shall pay SANOFI-AVENTIS the corresponding amount of VAT if applicable, within

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested
	 

	 	 	 	under 17 C.F.R. §§ 200.80(b)(4) and 
	 

	 	 	 	240.24b-2(b)(1)

3

 

	 	 	thirty (30) days of the receipt of the corresponding invoice, by bank transfer to the account
indicated on said invoice.
	 
	 	 	By express agreement between the Parties, pursuant to Article 7 of the IL-13 Agreement, this
amount shall be paid by IDM provided that it can be offset against an equal amount owed by
SANOFI-AVENTIS to IDM for the shares subscribed through the exercise of BSA 1 warrants on the
date of the offset.
	 
	4.1.2.	 	In consideration of the rights granted by SANOFI-AVENTIS to IDM under
this Agreement for the Marketing of Final IL-13 Products, IDM shall pay to SANOFI-AVENTIS a
sum equal to [...***...] before taxes. IDM shall pay SANOFI-AVENTIS the corresponding amount of
VAT, if applicable, within thirty (30) days following receipt of the corresponding invoice, by
bank transfer to the account indicated on the invoice.
	 
	 	 	By express agreement between the Parties, pursuant to Article 7 of the IL-13 Agreement,
this amount shall be paid by IDM provided that it can be offset against an equal amount owed
by SANOFI-AVENTIS to IDM for the shares subscribed through the exercise of BSA 2 warrants on
the date of the offset.
	 
	4.2.	 	Royalties on sales
	 
	 	 	In consideration of the right granted by SANOFI-AVENTIS to IDM to market IL-13 Products and
IL-13 Research Kits, IDM shall pay SANOFI-AVENTIS a royalty equal to [...***...] of the Net Sales
volume acheived by IDM in connection with this marketing. Net Sales acheived by
SANOFI-AVENTIS as an IDM licensee in application of the 2001 Agreement shall not be included
in the Net Sales base.
	 
	 	 	IDM shall maintain a special set of books, with the corresponding supporting
documentation, including all elements necessary for calculating the amount payable by
IDM to SANOFI-AVENTIS pursuant to the provisions above. SANOFI-AVENTIS may cause these
books to be verified, at its simple request made with sufficient advance notice, by an
independent expert chosen jointly by the Parties and, absent an agreement within fifteen
(15) days of the date on which SANOFI-AVENTIS has requested the audit, by the Presiding
Judge of the Lower Court of Paris on the petition of the first-acting Party. The expert
shall use his best efforts to notify his findings within a period of thirty (30) days
after referral of the case. The findings of this expert shall be final and without
recourse. The expert’s fees and costs will be paid by SANOFI-AVENTIS except if the
total amount owed by IDM to SANOFI-AVENTIS is more than five per cent (5%) greater than
the amount reported by IDM, in which case these costs and fees shall be paid by IDM.”

ARTICLE 5 – LIABILITY / INSURANCE

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested
	 

	 	 	 	under 17 C.F.R. §§ 200.80(b)(4) and 
	 

	 	 	 	240.24b-2(b)(1)

4

 

	5.1.	 	Without prejudice to the provisions of common law, IDM shall assume any responsibility that
might arise from the implementation of the IL-13 Development Programs, as well as from the
exploitation of the results, vis-à-vis any Third Party and on any basis whatsoever, and in
particular on the basis of civil liability, in particular with respect to any damage that
might result from the use (in carrying out the Phase I and II Studies) of the IL-13 shipped by
SANOFI-AVENTIS and not manufactured in accordance with “Good Manufacturing Practices”).
	 
	 	 	IDM alone shall also assume any liability that might arise (i) from any fault committed by it
or by any IDM Affiliate or sub-licensee within the context of the implementation of this
IL-13 Agreement, as well as (ii) for any failure on its part or on the part of any IDM
Affiliate or sub-licensee to perform its obligations pursuant to said IL-13 Agreement.
	 
	 	 	IDM shall also hold SANOFI-AVENTIS harmless with regard to any harmful consequences that
might arise for SANOFI-AVENTIS from any action brought against SANOFI-AVENTIS by a Third
Party based on damage of any kind whatsoever resulting from the circumstances indicated
above.
	 
	 	 	IDM warrants that it has taken out, at its sole expense, the necessary insurance coverage on
terms and conditions consistent with the practices in the pharmaceutical industry, in order
to sufficiently cover any risks that might result from the implementation of the IL-13
Development Programs and/or the marketing of the IL-13 Research Kits and/or the Final IL-13
Products. It shall provide evidence of such coverage at the request of SANOFI-AVENTIS.
	 
	5.2.	 	Without prejudice to the provisions of common law, SANOFI-AVENTIS
shall assume the liability that could result (i) from any fault committed by it or by any
Affiliate or sub-licensee of SANOFI-AVENTIS within the context of the execution of this IL-13
Agreement, (ii) of any failure by it or by any SANOFI-AVENTIS Affiliate or sub-licensee to
meet the its obligations under said Agreement as well as (iii) the shipment by it of IL-13
that is not up to the contractual specifications.
	 
	 	 	Consequently, it guarantees IDM against all prejudicial consequences that might arise for IDM
from an action brought against it by a Third Party based on damage of any kind whatsoever
resulting from the circumstances identified above.
	 
	 	 	SANOFI-AVENTIS guarantees that it has taken out the necessary insurance at its sole expense,
on terms and conditions consistent with the practices of the pharmaceutical industry, in
order to provide sufficient coverage of the risks likely to arise from the quantities of
supplied IL-13.
	 
	5.3.	 	The above provisions do not apply to the SANOFI-AVENTIS IL-13
Development Programs, which are governed by the 2001 Agreement.

5

 

ARTICLE 6 : GUARANTEES AND OBLIGATIONS OF SANOFI-AVENTIS

	6.1.	 	Existence of the IL-13 Intellectual Property and maintenance of IL-13
Patents
	 
	 	 	SANOFI-AVENTIS guarantees to IDM the existence of the IL-13 Patents and IL-13 Know-how and
the accuracy of its facts. In addition, SANOFI-AVENTIS declares that it is sole owner of the
IL-13 Patents and IL-13 Know-how and guarantees that it can freely and validly grant the
rights to said IL-13 Patents and IL-13 Know-how that it is granting under this IL-13
Agreement, the Contributions Agreement, the IL-13 License Agreement and the Amendment to the
IL-13 License Agreement. The above guarantees are made subject to the statements included in
Annex 10 of the IL-13 Agreement, in particular as regards the existence on the territory of
the United States of patents filed by [...***...] SANOFI-AVENTIS agrees to keep the IL-13 Patents
in force in accordance with applicable legal and regulatory provisions, in particular by
carrying out, at the appropriate time, necessary procedures and formalities, provided that,
in the event of an extension of the IL-13 Patents or corresponding supplementary protection
certificates, IDM has provided it with all necessary documents and signatures, when the MA of
the Final IL-13 Product is not in the name of SANOFI-AVENTIS. All costs pertaining thereto
shall be paid by SANOFI-AVENTIS.
	 
	6.2	 	6.2 Defense of IL-13 Intellectual Property
	 
	 	 	SANOFI-AVENTIS will have the obligation, at its sole expense :

	 	(a)	 	to defend in all circumstances the IL-13 Intellectual Property covered by this
agreement, specifically by conducting, both as plaintiff and respondent, both in France
and abroad, all actions permitted by law to the holder of IL-13 Intellectual Property ;
	 
	 	(b)	 	to inform IDM as soon as possible of all actions (as plaintiff and as respondent),
either current or proposed, as well as of any threat of fact or law to the IL-13
Intellectual Property of which it might learn and that could have a significant effect
on the use of the IL-13 Intellectual Property ;
	 
	 	(a)	 	in any event, not to create any obstacle in fact or in law
to the
possible intervention of IDM in a given proceeding, provided such
intervention does not appear capable of significantly harming the
interests of SANOFI-AVENTIS.

	 	 	IDM shall have the obligation, at its sole expense, to advise SANOFI-AVENTIS of any breach by
Third Parties of the IL-13 Intellectual Property rights of which it may have knowledge.
	 
	 	 	The Parties, in view of the fact that certain jurisdictions, including French law, do not
allow the non-exclusive holder of intellectual rights to act alone,

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested
	 

	 	 	 	under 17 C.F.R. §§ 200.80(b)(4) and 
	 

	 	 	 	240.24b-2(b)(1)

6

 

	 	 	consider as essential the obligation incumbent upon SANOFI-AVENTIS under this Article 6.2.
	 
	 	 	SANOFI-AVENTIS is bound by the obligation arising under this Article 6.2 only provided the
costs it incurs in complying with the obligation remain reasonable with respect to the stakes
and probability of success of the actions brought. Consequently, if said costs seem
unreasonable to SANOFI-AVENTIS, it is understood that the Parties shall come together to
examine, in good faith, any alternative solution that might be suitable in view of the
objectives sought by each of the Parties.

ARTICLE 7 : IMPROVEMENTS

	7.1.	 	Improvements made or acquired by SANOFI-AVENTIS
	 
	7.1.1.	 	SANOFI-AVENTIS shall retain sole and full title to all Improvements that it makes or
acquires.
	 
	 	 	In order to enable IDM to have IL-13 manufactured, SANOFI-AVENTIS shall transmit to IDM free
of charge and as soon as possible any improvement related to the manufacturing and production
processes and/or methods for IL-13 and IL-13 made pursuant to “Good Manufacturing Practices”
that it may have at its disposal during the life of this Agreement in a physically
transmissible form, and to which it shall have unencumbered access.
	 
	 	 	With respect to Improvements other than those specified in the preceding paragraph, in the
event SANOFI-AVENTIS wishes to make these Improvements available to any Third Party, it
irrevocably agrees to offer them to IDM on conditions, especially financial conditions, at
least equal to the most favorable conditions offered to any Third Party, during the life of
the IL-13 Agreement and of this Agreement.
	 
	7.1.2.	 	Use of the IL-13 Intellectual Property specified in the Contributions
Agreement and all rights granted by SANOFI-AVENTIS to IDM under the IL-13 Agreement, and this
Agreement shall fully extend to Improvements transmitted pursuant to the provisions of Article
7.1.1 above, as soon as they are known, and SANOFI-AVENTIS shall, on its own initiative and at
its own expense, carry out all necessary formalities and procedures to guarantee the effective
implementation of this provision. IDM agrees to participate, if necessary, in this protection
and, in particular, to sign all necessary acts and documents.
	 
	7.1.3.	 	Subject to the provisions of Article 7.1.1, it is expressly agreed by
the Parties that the transfer of Improvements by SANOFI-AVENTIS shall not entail any change to
the financial terms and conditions related to the payment of the Contributions and to this
Agreement.
	 
	7.2.	 	Improvements made or acquired by IDM

7

 

	7.2.1.	 	IDM shall retain sole and full title to all results, tangible or
intangible, patentable or non-patentable, patented or not patented, arising from the IL-13
Development Programs or from any improvements to its own patents that it may make or acquire.
	 
	 	 	SANOFI-SYNTHELABO unconditionally and irrevocably agrees not to claim any right
whatsoever to IDM’s research or inventions.
	 
	 	 	It shall be the responsibility of IDM, if it so wishes, to carry out at its own expense
all necessary formalities and steps to ensure the protection of its rights under applicable
statutes, and SANOFI-SYNTHELABO agrees to participate if necessary in this protection and, in
particular, to sign all necessary acts and documents.
	 
	7.2.2.	 	The above provisions apply subject to any conflicting provisions of the
2001 Agreement.

ARTICLE 8 : CONFIDENTIALITY

	8.1.	 	The confidentiality agreement executed on May 23, 1997 remains in
effect in all its provisions that are not in conflict with the stipulations of this IL-13
License Agreement and shall, by express agreement between the Parties, continue to be
binding upon them for the entire life of this IL-13 License Agreement and for a period of ten
(10) years following its expiration.
	 
	8.2.	 	Absent any legal, regulatory or judicial constraint, each Party
agrees not
to disclose this Agreement and/or its annexes, to engage in any publicity and/or to issue
any press release as to the signing and the content of this Agreement without the prior
authorization of the other Party, which authorization may not be refused without just
cause. In no event may the provisions of this Agreement be construed as prohibiting IDM
from providing information on the results of the work relative to the IL-13 Development
Programs.

ARTICLE 9 : TERM – CANCELLATION

	9.1.	 	This Agreement shall take effect on its execution date.
	 
	9.2.	 	Subject to the provisions of Articles 9.3. and 9.4. below, the rights thus conferred to IDM
by SANOFI-AVENTIS under this Agreement are granted for a term equal to the term of the legal
protection attaching to the IL-13 Patents. This IL-13 License Agreement shall terminate, in
each of the countries concerned, on the expiration date of the last IL-13 Patent relative to
that country.
	 
	9.3.	 	The provisions of Article 9.2., notwithstanding, SANOFI-AVENTIS may cancel this Agreement by
means of a written notice given at least sixty (60) days in advance if, on the expiration date
of a period of five (5) years calculated as of

8

 

	 	 	the filing of the first application for a
Reference MA, such MA has not been obtained and there is no on-going SANOFI-AVENTIS IL-13
Development Program.
	 
	 	 	The provisions of Article 9.2. notwithstanding, this Agreement shall be automatically
cancelled if no Reference MA has been obtained as of the expiration date of the IL-13
Agreement and there is, on that date, no on-going SANOFI-AVENTIS IL-13 Development Program

ARTICLE 10 – Assignment of the IL-13 Agreement 

	10.1.	 	Assignment of the Agreement by SANOFI-AVENTIS 
	 
	 	 	SANOFI-AVENTIS shall have the right to freely transfer the rights arising globally from
the IL-13 Patents, IL-13 Know-how, the IL-13 Agreement, the Contributions Agreement, and
this Agreement (in any form whatsoever, and specifically in the form of assignment,
contribution, exchange, merger, etc.) and shall be released from any obligation under said
agreements as of the date of their transfer.
	 
	 	 	In the event of the isolated transfer of these agreements, SANOFI-AVENTIS agrees to advise
IDM of such a transfer not less than fifteen (15) days prior to the date set for such
transfer, subject to any legal, regulation or contractual non-disclosure obligation
regarding this information that is incumbent upon SANOFI-AVENTIS.
	 
	 	 	In the event of the transfer of this package as part of a transfer by SANOFI-AVENTIS of
all or part of its activities, SANOFI-AVENTIS agrees to advise IDM of such transfer not
less than fifteen (15) days prior to the date of such transfer, subject to any legal,
regulatory or contractual non-disclosure obligation regarding this information that is
incumbent upon SANOFI-AVENTIS.
	 
	 	 	In both hypotheses contemplated above, the agreement implementing the transfer shall
expressly indicate that the beneficiary of the transfer shall be bound by all obligations
incumbent upon SANOFI-AVENTIS under the IL-13 Agreement, the Contributions Agreement, and
this Agreement.
	 
	 	 	In the event the above-referenced transfer is made to a SANOFI-AVENTIS Affiliate,
SANOFI-AVENTIS agrees (i) jointly with the Affiliate that the latter shall fulfill the
obligations incumbent upon the Affiliate under the IL-13 Agreement, the Contributions
Agreement, and this Agreement and (ii) in the event the transferee subsequently ceases to
be one of its Affiliates, to cause the rights and obligations to be re-transferred ahead
of time to itself or to another Affiliate.
	 
	10.2.	 	Assignment of the Agreement by IDM
	 
	 	 	IDM recognizes that its rights under this IL-13 Agreement, the Contributions

9

 

	 	 	Agreement, and
this Agreement, are strictly personal. On that basis, and subject to the provisions set
forth below, IDM agrees not to assign, transfer or convey its rights to anyone, whether
directly or indirectly, in whole or in part, against payment or free of charge, without
prior written authorization from SANOFI-AVENTIS. IDM further agrees not to confer to any
Third Party any right of any kind whatsoever on the Contributions.
	 
	 	 	By way of exception to the above provisions, IDM may:

	 	(a)	 	assign, transfer or transmit its rights and obligations arising
from this Agreement to any of its Affiliates, subject to the two following cumulative
conditions: (i) that IDM agrees, in the event the transferee were subsequently to cease
to be an IDM Affiliate, to cause the rights and obligations to be first re-transferred
to IDM or to any other IDM Affiliate, (ii) that IDM shall be the joint guarantor that
this Affiliate shall respect these rights and obligations;
	 
	 	(b)	 	transfer its rights and obligations under the IL-13 Agreement,
the Contributions Agreement, and this Agreement following a takeover of IDM by another
company or the dissolution of IDM through a merger of capital assets and holdings
pursuant to the provisions of Article 1844-5 of the French Civil Code.
	 
	 	(c)	 	transfer its rights and obligations under the IL-13 Agreement,
the Contributions Agreement, and this Agreement as a result of the assignment or
contribution of all its activities to an entity other than an Affiliate.

ARTICLE 11 : MISCELLANEOUS

	11.1.	 	Notices
	 
	 	 	All notices under this IL-13 License Agreement shall be given by registered letter with
return receipt sent to the addresses indicated in the header of this Agreement or to any
other address that may be made known in advance to one or the other Party.
	 
	11.2.	 	Power of Attorney
	 
	 	 	Power of Attorney is given to the bearer of a copy or excerpt of this agreement in order
to carry out all formalities, and in particular in order to cause this agreement to be
filed with the National offices of the relevant countries.
	 
	11.1.	 	Publicity – Recording
	 
	 	 	Notice of this Agreement shall be given by IDM to the Bureau of Transfers of the National
Institute of Industrial Property (Institut National de la Propriété Industrielle) and/or
listed with the relevant foreign Industrial Property offices,

10

 

	 	 	and the Parties agree here and
now to sign all documents, power-of-attorney and other powers necessary to the implementation
and registration of this Agreement in order to make it opposable to Third Parties in all
countries.
	 
	 	 	In the event this Agreement is registered, all costs and fees relative to such formality
shall be paid by IDM.

ARTICLE 12 : DISPUTES

Any differences arising from this IL-13 Agreement or in connection with it shall be permanently
resolved in accordance with the Rules of Arbitration of the International Chamber of Commerce, by
one or more arbitrators named pursuant to these Rules. The law governing this IL-13 License
Agreement shall be French law, the place of arbitration shall be Paris and the language of
arbitration shall be French.

Executed in Paris on August 12, 2005, in two (5) originals.

	 	 	 	 	 	 	 	 	 
	IDM	 	SANOFI-AVENTIS	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Hervé Duchesne de Lamotte	 	/s/ Jean-Pierre KERJOUAN	 	 
	 	 	 	 	 
	By:

	 	Hervé Duchesne de Lamotte
	 	By:
	 	Jean-Pierre KERJOUAN	 	 
	 

	 	CFO
	 	 	 	Advisor to the President,	 	 
	 

	 	 	 	 	 	General Counsel	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	/s/ Jean-Claude MULLER	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	By:
	 	Jean-Claude MULLER	 	 
	 

	 	 	 	 	 	Senior Vice President Scientific	 	 
	 

	 	 	 	 	 	and Medical Operations	 	 
	 

	 	 	 	 	 	Administration and Ressources	 	 

11

 

LIST OF ANNEXES TO THE AMENDED AND RESTATED IL-13 LICENSE AGREEMENT

			
	Annex 1 :	 	Updated description of IL-13 Patents

			
	Annex 2 :	 	List of on-going IL-13 Development Programs

			
	Annex 4.2.:	 	List of countries covered by claims under the [...***...] patents

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested
	 

	 	 	 	under 17 C.F.R. §§200.80(b)(4) and 
	 

	 	 	 	240.24b-2(b)(1)

12

 

Annex 1

TO THE AMENDED AND RESTATED IL-13 LICENSE AGREEMENT

UPDATED DESCRIPTION OF IL-13 PATENTS

[...***...]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	[...***...]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested
	 

	 	 	 	under 17 C.F.R. §§ 200.80(b)(4) and 
	 

	 	 	 	240.24b-2(b)(1)

13

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	[...***...]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested
	 

	 	 	 	under 17 C.F.R. §§ 200.80(b)(4) and 
	 

	 	 	 	240.24b-2(b)(1)

14

 

Annex 2

TO THE AMENDED AND RESTATED IL-13 LICENSE AGREEMENT

LIST OF ON-GOING IL-13 DEVELOPMENT PROGRAMS

UVIDEM

COLLIDEM

[...***...]

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested
	 

	 	 	 	under 17 C.F.R. §§ 200.80(b)(4) and 
	 

	 	 	 	240.24b-2(b)(1)

15

 

ANNEX 4.2

TO THE AMENDED AND RESTATED IL-13 LICENSE AGREEMENT

Llist of countries covered by claims of the [...***...] patents

[...***...]

[...***...]

[...***...]

[...***...]

[...***...]

[...***...]

[...***...]

[...***...]

	 	 	 	 	 
	 

	 	*
	 	Confidential Treatment Requested
	 

	 	 	 	under 17 C.F.R. §§200.80(b)(4) and 
	 

	 	 	 	240.24b-2(b)(1)

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]